curriculum vitae - chicago medicine · web viewsupervised the research project of mr. lessner, an...

CURRICULUM VITAEThomas G Boyer, Ph.D.

GENERAL INFORMATION Date of Preparation: 06/07/2018

PERSONAL DATA:

Address:

Department of Molecular MedicineUniversity of Texas Health Science Center at San Antonio8210 Floyd Curl Drive San Antonio, TX 78229

Phone Number: (210) 562-4151

Fax Number: (210) 562-4164

Email Address: [email protected]

EDUCATION AND TRAINING:

Undergraduate Training

Year Degree Discipline Institution/Location

1983

1983

BS

BS

Wildlife Fisheries Management

Biology

Frostburg State University, Frostburg, MD

Frostburg State University, Frostburg, MD

Honors Thesis Advisor: Dr. Amy Harmon, Ph.D.

Graduate Training

Year

1990

Degree

PhD

Discipline

Biochemistry

Institution/Location

State University of New York at BuffaloRoswell Park Graduate DivisionBuffalo, NY

Advisor: Lynne E. Maquat, Ph.D. Dissertation: Transcriptional regulation of the housekeeping gene for human triosephosphate Isomerase

Post-Doctoral Training Year Discipline Institution/Location

1991- Biochemistry/ University of California,

1

1998 Molecular Genetics Los Angeles, CA Mentor: Arnold J. Berk, M.D. Research: Identification and characterization of the human RNA polymerase II transcriptional Mediator

ACADEMIC APPOINTMENTS:

08/2010 – Present

08/2005 – 07/2010

Professor

Associate Professor

The University of Texas Health Science Center at San Antonio, Department of Molecular Medicine, San Antonio, TX


08/2000 - 07/2005

Assistant Professor The University of Texas Health Science Center at San Antonio, Department of Molecular Medicine, San Antonio, TX

04/1999 - 07/2000

Assistant Professor Research


NON-ACADEMIC APPOINTMENTS:

01/2001 -12/2005

Director, San Antonio Cancer Institute Mass Spectrometry TRP Satellite Core


HONORS AND AWARDS:

2005 Executive Research Committee Merit Payment in Recognition of Research Endeavors

2004 Executive Research Committee Merit Payment in Recognition of Research Endeavors

2003

2003

U.S. Army Department of Defense Research Awards Recognition: Alamo Breast CancerFoundation

IDEA Award: U.S. Army Department of Defense Breast Cancer Research Program

2002

2001

Career Development Award: U.S. Army Department of Defense Breast Cancer ResearchProgram

IDEA Award: U.S. Army Department of Defense Breast Cancer Research Program

1999 Parvin Postdoctoral Recognition Award: University of California, Los Angeles

1995 American Cancer Society: Senior Postdoctoral Research Fellowship

1991 American Cancer Society: Junior Postdoctoral Research Fellowship

1990 California Institute for Cancer Research Fellowship

1983 Magna Cum Laude and Departmental Honors in Biology: Frostburg State University

PROFESSIONAL DEVELOPMENT:

Date Description

2009 Collaborative Institutional Training Initiative

2

Instructional course: “The Protection of Human Subjects Research”. Curriculum included topics spanning history and ethical principles, basic IRB regulations and review process, records-based research, FDA-regulated research, HIPAA and human subjects research.

2001 Applied Biosystems Voyager Mass Spectrometry Workstation Training; Framingham, MACompleted instructional course in the theory, operation, maintenance and practical applications of Voyager MALDI-TOF mass spectrometer Framingham, MA

TEACHING

LEADERSHIP/ADMINISTRATION/CURRICULUM DEVELOPMENT: Date Activity Level Role

09/2014 -09/2016

01/2006 - 12/2006

09/2003 -

Integrated Biomedical Sciences (IBMS) Cell Biology, Genetics and Molecular Medicine (CGM) Leadership CommitteeIn 2012, the IBMS replaced the IMGP as the flagship biomedical sciences training program within the Graduate School of Biomedical Sciences (GSBS). The IBMS is an integrated, multidisciplinary program composed of seven disciplines across basic science and clinical departments, one of which CGM. The CGM Leadership Committee is charged with the development, review, and amendment of academic policies and procedures related to the CGM discipline, including student curriculum and academic guidelines, student recruitment, faculty appointments, and CGM outreach and advertisement.

IMGP Core Curriculum Development CommitteeParticipated in the design, structure, and organization of the major foundational core course “Fundamentals of Biomedical Sciences” (INTD 5000) required for all first-year students enrolled in the new flagship Integrated Multidisciplinary Graduate Program (IMGP). In 2008, the IMGP replaced the former discipline-based and departmental-administered doctoral programs within the Graduate School of Biomedical Sciences (GSBS). The IMGP, now the largest Ph.D. program within the GSBS, represents an umbrella graduate program comprised of eleven multidisciplinary tracks, which address the most significant training areas in biomedicine. These include Biology of Aging, Cancer Biology, Cell & Molecular Biology, Genetics, Genomics, & Development, Membrane Biology & Cell Signaling, Metabolism & Metabolic Disorders, Microbiology & Immunology, Molecular Biophysics & Biochemistry, Molecular, Cellular & Integrative Physiology, Neuroscience, and Pharmacology. As a member of the IMGP Core Curriculum Development Committee, I contributed significantly to the creation and establishment of the 8-credit IMGP interdisciplinary core course designed to provide a basic foundation for first-year Ph.D. students, prior to their matriculation into specialized tracks, in the fundamentals of biochemistry, molecular biology, cell biology, microbiology, immunology, and organismal & systems biology.

Committee on Graduate Studies (COGS)

Graduate

Graduate

Member

Member

Chair

3

11/2007

Graduate Program in Molecular MedicineAs Chair of the Molecular Medicine GOGS, I was responsible for oversight and administration of the Graduate Program in Molecular Medicine, one of the major Ph.D. programs within the GSBS. These duties included coordination, evaluation, and modification of the Molecular Medicine Graduate Program curriculum, including both didactic and practical training (MMEDD 6016 Advanced Molecular and Cellular Biology; MMED 5015 Modern Methods in Molecular and Cellular Biology; MMED 5019 Graduate Colloquium; MMED 5001 Molecular Medicine; MMED 6091 Seminars on Molecular Medicine; MMED 6097 Supervised Research; MMED 6071 Supervised Teaching; MMED 7099 Dissertation Research).

Graduate

COURSE BASED TEACHING:

(*Indicates Interdisciplinary Teaching Outside of Department)

Date Course Name Level Role

09/2014 - 08/2016

09/2014 - 08/2016

09/2013 - Present

Preparation Hrs: 24; Student Contact Hrs: 1.5; Average Number of Students: 110INTD 5082 Responsible Conduct of Research*Lectured to medical residents, fellows, and students (Medical School) as well as research students and fellows (GSBS) regarding policies and procedures related to scientific integrity, with an emphasis on scientific misconduct.

Preparation Hrs: 24; Student Contact Hrs: 2; Average Number of Students: 110MEDI 5070 Responsible Conduct of Patient Oriented Clinical Research*Lectured to medical residents, fellows, and students (Medical School) as well as research students and fellows (GSBS) regarding policies and procedures related to scientific integrity, with an emphasis on scientific misconduct.

Preparation Hrs: 16; Student Contact Hrs: 2; Average Number of Students: 6RADI 5025 Radiation Biology and Molecular Oncology*Lectured, tested, and graded students on fundamental theories and emerging concepts as well as modern methods pertaining to regulation and oncogenic dysregulation of eukaryotic gene expression.

Medical

Medical

Medical

Lecturer

Lecturer

Lecturer

09/2000 - Present

Preparation Hrs: 10; Student Contact Hrs: 2; Average Number of Students: 12MMED 5015 Modern Methods in Molecular and Cellular BiologyLectured, examined, and graded students on theories, concepts and practical applications of mass

Graduate Lecturer

4

spectrometry and protein purification and analysis.

09/1999 - 12/2012

09/2001 -12/2012

Preparation Hrs: 32; Student Contact Hrs: 8; Average Number of Students: 12MMED 6016 Advanced Molecular Cell BiologyLectured, examined, and graded students on fundamental theories and emerging concepts as well as modern methods pertaining to RNA polymerase II and III transcription.

Preparation Hrs: 6; Student Contact Hrs: 3; Average Number of Students: 12MMED 5019 Graduate ColloquiumMonitored and directed student presentation, discussion and critical evaluation of original scientific literature pertaining to RNA polymerase II transcription.

Graduate

Graduate

Lecturer

Lecturer

09/2001 - 08/2007

Preparation Hrs: 12; Student Contract Hrs: 3; Average Number of Students: 12MMED 6017, Cellular Responses to DNA Damage Monitored and directed student presentation, discussion and critical evaluation of scientific literature pertinent to control of gene expression and genomic stability in response to DNA damage. This was an advanced elective course offered to senior graduate students as a required component of the Department of Molecular Medicine NIH training grant in DNA repair mechanisms, upon which I was a participating investigator.

Graduate Instructor

04/2004 - 04/2006

Preparation Hrs: 15; Student Contract Hrs: 2; Average Number of Students: 14CSBL 6068 Molecular Oncology*Lectured, examined, and graded students on fundamental theories and emerging concepts as well as modern methods relating to hereditary breast cancer, with an emphasis on the breast tumor suppressors BRCA1 and BRCA2

Graduate Lecturer

OTHER TEACHING:

STUDENT TRAINING/GUIDANCE/MENTORING (Total number of students/trainees: 184)

Membership on Supervising Committees (Total number of students: 91)

Qualifying Examination Committees (Total number of students: 41)

Date Description Institution

12/2017 – Present Bogang Wu UTHSCSAResearch Topic: Mir-145 directs mesenchymal stem cell fate through targeting Oct4. Mr. Wu is an IBMS student in the laboratory of Dr. Rong Li, Department of Molecular Medicine, UTHSCSA.

5

04/2017 – 07/2017 Xiaoyu Yang UTHSCSAResearch Topic: Inducing massive micropinocytosis for lung cancer treatment. Ms. Yang is an IBMS student in the laboratory of Dr. Tim Huang, Department of Molecular Medicine, UTHSCSA.

04/2016 – 05/2016 Jeff Cooney UTHSCSAResearch Topic: Role of C10orf58 in myeloid lineage commitment and oxidative stress. Mr. Cooney is an IBMS student in the laboratory of Dr. Ricardo Aguiar, Department of Medicine, UTHSCSA.

06/2016 – present Hongjoo An UTHSCSAResearch Topic: Role of CBP/p300 in myelodysplastic syndrome. Mr. An is an IBMS student in the laboratory of Dr. Alex Bishop, Department of Cell Systems and Anatomy, UTHSCSA.

11/2014 – 03/2015 Phillip Webster UTHSCSAResearch Topic: Co-transcriptional splicing is regulated via interactions of nucleoporin subunits of the nuclear pore complex. Mr. Webster is an IBMS student in the laboratory of Dr. Alfred Fisher, Department of Medicine, UTHSCSA.

04/2014 – 08/2014 Sun Kyung UTHSCSAResearch Topic: Characterization of chloroplast signal recognition particle 43 subunit (cpSRP43) interaction with light-harvesting chlorophyll a/b-binding protein (LHCP) during ATP-dependent chaperoning activity of cpSRP43. Ms. Kyung is an IBMS student in the laboratory of Dr. Andrew Hinck, Department of Biochemistry, UTHSCSA.

02/2014 – 04/2014 Nick Dybdal-Hargreaves UTHSCSAResearch Topic: Impaired Notch Signaling Represents a Therapeutically Distinct Subtype of HNSCC. Mr. Dybdal-Hargreaves is an IBMS student in the laboratory of Dr. Susan Mooberry, Department of Pharmacology, UTHSCSA.

02/2013 – 04/2013 Keith Ashcraft UTHSCSAResearch Topic: Influence of matrix rigidity on cancer associated fibroblasts. Mr. Ashcraft is a Molecular Medicine student in the laboratory of Dr. Rong Li, Department of Molecular Medicine, UTHSCSA.

02/2013 – 05/2013 Alison Doyungan UTHSCSAResearch Topic: JNK signaling: a potential mediator of aerobic glycolysis in hepatocellular carcinoma. Ms. Doyungan is an IMGP student in my laboratory, Department of Molecular Medicine, UTHSCSA.

02/2013 – 07/2013 Chen Chen UTHSCSAResearch Topic: Gemcitabine resistance of pancreatic cancer is due in part to overexpression of Nrf2. Ms. Chen is an IMGP student in the cancer biology track, UTHSCSA.

02/2011 – 15/2011 Cory Holland UTHSCSAResearch Topic: Role of Rad1 in the repair of intrastrand crosslinks. Mr. Holland is a Molecular Medicine student in the laboratory of Dr. Sang Lee, Department of Molecular Medicine, UTHSCSA.

08/2010 – 12/2011 Jun Ho Ko UTHSCSAResearch Topic: The role of Recq15 in regulation of Rad51 filament formation. Mr. Ko is a Molecular Medicine student in the laboratory of Dr. Paul Hasty, Department of Molecular Medicine, UTHSCSA.

07/2010 – 01/2011 Balaji Parameswaran UTHSCSAResearch Topic: The role of BRCA1 in DNA DSB repair. Mr. Parameswaran is a Molecular Medicine student in the laboratory of Dr. Yanfen Hu, Department of Molecular Medicine, UTHSCSA.

6

06/2010 – 09/2010 Wei Zhang UTHSCSAResearch Topic: Entry and trafficking pathway of rhesus rhadinovirus. Dr. Zhang was a Molecular Medicine student in the laboratory of Dr. Shou-Jiang Gao, Department of Pediatrics, UTHSCSA.

05/2010 – 07/2010 Sreejith Nair UTHSCSAResearch Topic: Role of the BRCA1 cofactor COBRA in mammary gland development and tumorigenesis. Dr. Nair was a Molecular Medicine student in the laboratory of Dr. Rong Li, Molecular Medicine.

12/2008 – 07/2009 Guem Hee Baek UTHSCSAResearch Topic: Ufd2 mediated proteolysis. Dr. Baek was a Molecular Medicine student in the laboratory of Dr. Hai Rao, Department of Molecular Medicine, UTHSCSA.

09/2008 – 08/2009 Jiangyun Zhu UTHSCSAResearch Topic: Role of vFLIP in CSAV-mediated tumorigenesis. Ms. Zhu was a Molecular Medicine student in the laboratory of Dr. Shou-Jiang Gao, Department of Pediatrics, UTHSCSA.

08/2007 – 06/2008 Srividya Madabhushi UTHSCSAResearch topic: The role of Allostery in Proteasome Regulation. Dr. Madabhushi was a Molecular Medicine student in the laboratory of Dr. Maria Gaczynska, Department of Molecular Medicine, UTHSCSA.

02/2007 – 06/2009 David New UTHSCSAResearch topic: The role of Nox4 NAD(P)H oxidase in IGF-1 signaling and diabetic nephropathy. Dr. New was a Molecular Medicine graduate student in the laboratory of Dr. Hanna Abboud, Department of Medicine-Renal Diseases, UTHSCSA.

09/2008 – 01/2009 Binoj Nair UTHSCSAResearch Topic: Evaluating the significance of PELP1 in DNA damage response pathway. Mr. Nair was a Molecular Medicine student in the laboratory of Dr. Ratna Vadlamudi, Department of Ob-Gyn, UTHSCSA.

01/2008 – 01/2009 Richard Tamfu UTHSCSAResearch Topic: Radiation-induced eNOS/ER-alpha Signaling in Breast Cancer Relapse and Metastasis. Dr. Tamfu was a Molecular Medicine student in the laboratory of Dr. Mohan Natarajan, Department of Radiation Oncology, UTHSCSA.

09/2007 – 02/2009 Tiffany Jones UTHSCSAResearch topic: The role of vCyclin in KSHV mediated tumorigenesis. Dr. Jones was a Molecular Medicine student in the laboratory of Dr. Shou-Jiang Gao, Department of Pediatrics, UTHSCSA.

08/2007 – 10/2007 Jianlong Sun UTHSCSAResearch Topic: Role of Negative Elongation Factor Complex in the Regulation of Alternative Splicing. Dr. Sun was a student in the laboratory of Dr. Rong Li, Department of Molecular Medicine, UTHSCSA.

01/2007 – 05/2007 Lavinia Dumitrache UTHSCSAResearch Topic: Genetic role of BRCA2 in cancer. Dr. Dumitrache was a Molecular Medicine student in the laboratory of Paul Hasty. Dr. Dumitrache graduated from the Molecular Medicine Program in August 2009. She is a Postdoctoral Fellow at St. Jude's Research Hospital in Memphis, TN.

08/2006 – 08/2006 Jennifer Apodaca UTHSCSAResearch topic: Degradation of PrP in Yeast and Human. Dr. Apodaca graduated from the Molecular Medicine Program in 2008. Currently enrolled as a Graduate Student in the Physician Assistant Program, UTHSCSA. 03/2006 – 06/2006 Ji-Hyun Oum UTHSCSA

7

Research topic: The Role of Chromatin Remodeling RSC Complex in Repair of DNA Double Strand Breaks and Genome Maintenance. Dr. Oum graduated from the Molecular Medicine program in August 2009 and is currently a Postdoctoral Fellow in the laboratory of Dr. Sang Eun Lee, Department of Molecular Medicine.

08/2005 – 08/2005 Yu Wang UTHSCSA Withdrew from Graduate Program in Molecular Medicine, August 2005.

06/2005 – 08/2005 Mingjiu Chen UTHSCSAResearch topic: Functional study of the role of hTREX2 in maintaining genome integrity. Dr. Chen graduated from the Molecular Medicine Program in December 2006, and is currently employed as a Scientist at Abbott Laboratories in Worcester, MA.

05/2005 – 06/2005 Xiaolin Tan UTHSCSAResearch topic: Dissection of Proteasome Gating Mutants. Ms. Tan transfered from MMED PhD to MS program in August 2005.

05/2004 – 07/2004 Han Li UTHSCSAResearch topic: Ku Functions in Maintaining Mammalian Genomic Stability. Dr. Li graduated from the Molecular Medicine Program in May 2007 and is currently employed as a Postdoctoral Fellow, in the laboratory of Dr. Serrano in Madrid, Spain.

02/2004 – 06/2004 Valerie (Boka) Holcomb UTHSCSAResearch topic: The impact Ku80 has on aging and cancer. Dr. Boka graduated from the Molecular Medicine Program in May 2007, and is curently employed as a Postdoctoral Fellow in the Department of Human Ecology at UT-Austin.

02/2004 – 05/2004 Bingnan Gu UTHSCSAResearch topic: The role of CtIP in the mammalian DNA replication. Dr. Gu graduated from the Molecular Medicine Program in May 2006, and is currently employed as a Postdoctoral Fellow in the laboratory of Dr. Maller, Department of Biological Chemistry at the University of California, Irvine.

03/2003 – 04/2003 Wendy Bussen UTHSCSAResearch topic: Rad54B and BLM as Modulators of Homologous Recombination in Human Cells. Dr. Bussen graduated from the Molecular Medicine Program in July 2006, and is currently employed as a Postdoctoral Fellow in the Department of Radiation Oncology-Cancer Biology at Washington University.

10/2002 – 12/2002 Hui-Min Tseng UTHSCSA Research topic: End Processing in Microhomology-dependent Nonhomologous End Joining. Dr. Tseng graduated from the Molecular Medicine Program in April 2004 and is currently employed as a Postdoctoral Fellow, in the laboratory of Dr. Gunter Blobel at the The Rockefeller University.

02/2002 – 04/2002 Horng-Ru Lin UTHSCSAResearch topic: Mitotic Phosphorylation of BRCA2. Dr. Lin graduated from the Molecular Medicine Program in March 2006 and is currently employed as a Postdoctoral Fellow in the laboratory of Dr. Don Ganem, Department of Microbiology & Immunology at the University of California, San Francisco.

10/2001 – 12/2001 Song Zhao UTHSCSAResearch topic: S. Phase Checkpoint in S. Cerevisiae. Dr. Zhao graduated from the Molecular Medicine Program in May 2003 and is currently employed as a Research Fellow in the laboratory of Dr. Thomas Kelly, Department of Molecular Biology, Memorial Sloan-Kettering Cancer Center.

04/2001 – 06/2001 Deanna Jansen UTHSCSAResearch topic: Examination of mutants of the Rad50/Mre11/Xrs2 complex in DNA repair and meiotic processes of the biochemical functions of Sae2. Ms. Jansen withdrew from UTHSCSA in August 2001.

8

03/2001 – 05/2001 Stefan Sigurdsson UTHSCSAResearch topic: Action of Human Recombination Factors in DNA Strand Exchange Reaction. Dr. Sigurdsson graduated from the Molecular Medicine Program in May 2003 and is currently employed as a Postdoctoral Scientist in the Lab of Mechanisms of Gene Transcription, Dr. Jesper Svejstrup's Lab at the London Research Institute.

04/2000 – 02/2001 Stephen Van Komen UTHSCSAResearch topic: Functional Interactions of Yeast Rad51and Rdh54 Proteins with the Rad51 Recombinase. Dr. Van Komen graduated from the Molecular Medicine Program in October 2002 and is currently employed in an Industrial Position at Bristol-Myers Squibb in Boulder, Colorado.

10/1999 – 02/2000 Jill Gilroy UTHSCSAResearch topic: Role of platelet-derived growth factor receptor beta signaling in kidney development. Dr. Gilroy graduated from the Molecular Medicine Program in May 2002.

06/1999 – 09/1999 Sean Post UTHSCSAResearch topic: Creation of two stable cell lines expressing a dominant negative AT construct. Dr. Post graduated from the Molecular Medicine Program in August 2003 and did postdoctoral work at M.D. Anderson Cancer Center.

M.S. Thesis Examination Committees (Total number of students: 2)


09/2005 – 11/2005 Xiaolin Tan UTHSCSAThesis title: The role of protesomal gate in the regulation of proteasome function. Ms. Tan graduated from the Molecular Medicine Program with a Master‘s degree in December 2005. Ms. Tan is currently employed in a Research Position in the laboratory of Katerina Akassoglou, Department of Pharmacology at the University of California, San Diego.

08/2000 – 12/2000 Karl Rodriguez UTHSCSAThesis title: DNA nucleotide excision repair in Saccharomyces cerevisiae. Mr. Rodriguez received his M.S. degree from the Molecular Medicine Program in April 2001. He subsequently returned to the program in the Ph.D. Track and is in the laboratory of Dr. Maria Gaczynska, Department of Molecular Medicine.

Ph.D. Dissertation Committees (Total number of students: 48; *Chair on 13 Committees)


03/2015 – Present John Koprivsek UTHSCSADissertation title: To be determined. Mr. Koprivsek is an IBMS Ph.D. student in the laboratory of Dr. Jean Patterson, Department of Virology and Immunology, Texas Biomedical Research Institute, and Department of Microbiology and Immunology, UTHSCSA.

12//2017 – 04/2018 Lauren Prusinski Augusta UniversityDissertation title: Early life environmental and hormonal exposure and race-related influence on the human stem cell populations in human fibroid and myometrial tissues leads to compromised genomic integrity and increased fibroid tumorigenesis. Dr. Prusinski was Ph.D. student in the laboratory of Dr. Ayman A-Hendy, Department of Obstetrics/Gynecology at Augusta University. Dr. Prusinski graduated in 2018.

12/2015 – 01/2018 Kunhua Qin UTHSCSA

9

Dissertation title: Dissecting the functional role of Sirt6 in mouse pancreatic beta cell development and homeostasis. Dr. Qin was a Ph.D. student in the laboratory of Dr. Pei Wang, Department of Cellular and Structural Biology, UTHSCSA. Dr. Qin graduated in 2018.

07/2013 – 03/2017 Heather Hambright UTHSCSADissertation title: Differential Nrf2/Keap1/p62 responses during oxidative stress in melanomagenesis. Dr. Hambright was an IMGP Ph.D. student in the laboratory of Dr. Rita Ghosh, Department of Urology, School of Medicine, UTHSCSA. She is presently a postdoctoral fellow at UT Southwestern.

07/2013 – Present Min Ju Park UTHSCSA*Committee ChairDissertation title: The molecular basis of Mediator subunit MED12 in the pathogenesis of uterine fibroids. Dr. Park was a Molecular Medicine Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Park is currently a postdoctoral fellow at Rockefeller University.

01/2013 – 12/2017 Jacob Hemmi UTHSCSADissertation title: Barriers to cellular reprogramming and production of primate-derived induced pluripotent stem cells. Dr. Hemmi was an IBMS Ph.D. student in the laboratory of Dr. Peter Hornsby, Department of Cellular and Structural Biology, UTHSCSA. Dr. Hemmi graduated in 2018.

03/2017 – 09/2017 Emilia Kuuluvainen University of HelsinkiDissertation title: Function of the metazoan Mediator kinase module in transcription. Dr. Kuuluvainen was a Ph.D. student in the laboratory of Dr. Tomi Makala, Department of Biochemistry and Molecular Biology, University of Helsinski. Dr. Kuuluvainen graduated in 2017 and is currently a postdoctoral fellow at the University of Helsinki.

11/2014 – 05/2017 Keith Ashcraft UTHSCSADissertation title: Utilizing genomic approaches to identify biomarkers for poor outcome primary prostate cancer. Dr. Ashcraft was a Ph.D. student in the laboratory of Dr. Robin Leach, Department of Cellular and Structural Biology, UTHSCSA. Dr. Ashcraft graduated in 2017 and is currently a postdoctoral fellow at UTHSCSA.

10/2014 – 02/2017 Aaron Horning UTHSCSADissertation title: Identification of candidate gene markers for biochemical recurrence in prostate cancer. Dr. Horning was an Ph.D. student in the laboratory of Dr. Tim Hui-Ming Huang, Department of Molecular Medicine, UTHSCSA. Dr. Horning graduated in 2017 and is currently a postdoctoral fellow at Stanford University.

02/2015 – 04/2016 Rohit Jadhav UTHSCSADissertation title: Identifying cancer-type-specific DNA methylomes using computational and experimental approaches. Dr. Jadhav was a Ph.D. student in the laboratory of Dr. Victor Jin, Department of Molecular Medicine, UTHSCSA. Dr. Jadhav graduated in 2016.

08/2013 – 04/2015 Xiaowen Zhang UTHSCSADissertation title: Functional interaction between Brca1 and its co-factor Cobra1 in mammary gland. Dr. Zhang was a Ph.D. student in the laboratory of Dr. Rong Li, Department of Molecular Medicine, UTHSCSA. Dr. Zhang graduated from the Molecular Medicine Program in May 2015, and is currently a postdoctoral fellow at UTHSCSA.

07/2013 – 04/2016 Alison D. Clark UTHSCSA*Committee ChairDissertation title: Mediator kinase module as a transducer of oncogenic Wnt/-catenin signaling. Dr. Clark was an IMGP Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Clark graduated in 2016 and is currently a postdoctoral fellow at UTHSCSA.

05/2012 – 10/2016 Lindsey Barron-Myers UTHSCSA

10

Dissertation title: Utilizing protein interactions for cancer therapeutic potential. Dr. Barron was an IMGP Ph.D. student in the laboratory of Dr. Alex Bishop, Department of Cellular and Structural Biology, UTHSCSA. She graduated in 2016 and is currently a postdoctoral fellow at UTHSCSA.

04/2012 – Present Jingjing Gong UTHSCSADissertation title: NFkappaB/Stat3/Cox-2 signaling axis: novel target for pancreatic cancer. Ms. Gong was an IMGP Ph.D. student in the laboratory of Dr. Addanki Pratap Kumar, Department of Urology, School of Medicine, UTHSCSA. Dr. Gong graduated from the IMGP program in May December 2013, and is currently a postdoctoral fellow.

11/2011 – 11/2013 Cory Holland UTHSCSADissertation title: The role of Rad1 in instrastrand crosslink DNA repair. Mr. Holland was a Molecular Medicine Ph.D. student in the laboratory of Dr. Sang Lee, Department of Molecular Medicine, UTHSCSA. Dr. Holland graduated from the Molecular Medicine Program in December 2013, and is currently a lecturer in the Department of Chemistry and Biochemistry, Texas State University.

09/2011 – 12/2014 Fangjian Gao UTHSCSA*Committee ChairDissertation title: Mediator is a transducer of Sox17 signaling in definitive endodem development. Mr. Gao was a Molecular Medicine Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Gao graduated from the Molecular Medicine Program in December 2014, and is currently a postdoctoral fellow in the laboratory of Dr. Diana Hargreaves, Laboratory of Molecular and Cell Biology, Salk Institute, La Jolla, CA.

05/2011 – 11/2013 Monica Mann UTHSCSADissertation title: The epigenetic regulation of breast cancer progression by the proto-oncogene PELP1. Ms. Mann was an IMGP Ph.D. student in the laboratory of Dr. Ratna Vadlamudi, Department of Obstetrics-Gynecology, School of Medicine, UTHSCSA. Dr. Mann graduated from the IMGP program in December 2013, and is currently a postdoctoral fellow in the Department of Cancer Biology, MD Anderson Cancer Center, Houston, TX.

06/2010 -11/2011 Leah Hargrove UTHSCSADissertation title: BRCA1 regulation of aromatase expression. Ms. Hargrove was an IMGP Ph.D. student in the laboratory of Dr. Yanfen Hu, Department of Molecular Medicine, UTHSCSA. In November of 2011, Ms. Hargrove elected to convert to the Molecular Medicine Masters Degree program.

06/2010 – 07/2014 Penny Meng UTHSCSADissertation title: Biological role of E2F1 in cutaneous malignant melanoma. Ms. Meng was an IMGP Ph.D. student in the laboratory of Dr. Rita Ghosh, Department of Urology, School of Medicine, UTHSCSA. Dr. Meng graduated from the IMGP program in December 2014, and is currently a postdoctoral fellow in the laboratory of Dr. Paul Yaswen, Lawrence Berkeley National Laboratory, Berkeley, CA.

07/2009 – 05/2013 Nam Hee Kim UTHSCSA*Committee ChairDissertation title: Mediator and epigenetic control of neuronal gene expression and neural progenitor cell identity. Dr. Kim was a Ph.D. student under my mentorship. Dr. Kim graduated from the Molecular Medicine Program in May 2013, and is currently a temporary postdoctoral fellow under my mentorship while investigating permanent postdoctoral fellowships elsewhere.

06/2009 – 07/2013 Dong Hyun Kim UTHSCSADissertation title: CDK inihibitor proteolysis during DNA replication and a response to DNA damage. Dr. Kim was a Molecular Medicine Ph.D. student in the laboratory of Dr. P. Renee Yew, Department of Molecular Medicine, UTHSCSA. Dr. Kim graduated from the Molecular Medicine Program in May 2013, and is currently a postdoctoral fellow in the laboratory of Dr. Donald Cleveland, Ludwig Institute for Cancer Research, University of California, San Diego, CA.

11

03/2009 – 03/2013 Tiffany Jones UTHSCSADissertation title: The role of vCyclin in KHSV-mediated tumorigenesis. Dr. Jones was a Molecular Medicine Ph.D. student in the laboratory of Dr. Shou-Jiang Gao. Dr. Jones graduated from the Molecular Medicine program in May 2013 and is currently a postdoctoral fellow in the laboratory of Dr. Shou-Jiang Gao, Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California.

03/2009 – 04/2012 Jason Spaeth UTHSCSA*Committee ChairDissertation title: Molecular determinants and pathological disruption of a MED12-Cyclin C interface in Mediator. Dr. Spaeth was a Ph.D. student under my mentorship. Dr. Spaeth graduated from the Molecular Medicine program in April 2012 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Roland Stein, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.

02/2009 – 12/2012 Richard TamfuDissertation title: Radiation-induced eNOS/ER-alpha signaling in breast cancer relapse and metastasis. Mr. Tamfu was a Molecular Medicine student in the laboratory of Dr. Mohan Natarajan, Department of Radiation Oncology, UTHSCSA.

04/2008 – 06/2012 Shoujun Gu UTHSCSA*Committee ChairDissertation title: Basic helix-loop-helix protein Twist1 represses Sox9 in chondrogenesis. Dr. Gu was a Ph.D. student under my mentorship. Dr. Gu graduated from the Molecular Medicine program in June 2012 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Yingzi Yang, Genetic Disease Research Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland.

07/2009 – 07/2011 SeJIn Kim UTHSCSA*Committee ChairDissertation title: DBC-1 as a novel therapeutic target in endocrine resistant breast cancer. Dr. Kim was a Ph.D. student under my mentorship. Dr. Kim graduated from the Molecular Medicine program in July 2011 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Jeffrey M. Rosen, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

04/2009 – 07/2011 Xuan Xu UTHSCSA*Committee ChairDissertation title: Mediator is a transducer of amyloid- precursor protein-dependent nuclear signaling. Dr. Xu was a Ph.D. student under my mentorship. Dr. Xu graduated from the Molecular Medicine program in July 2011 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Ying E. Zhang, Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland.

12/2007 – 06/2009 Ji-Hyun Oum UTHSCSADissertation title: Role of Saccharomyces cerevisiae chromatin remodeling complex RSC in DSB repair. Dr. Oum graduated from the Molecular Medicine program in August 2009 and was a Postdoctoral Fellow in the laboratory of Dr. Sang Eun Lee, Department of Molecular Medicine.

11/2007 – 04/2009 Jianlong Sun UTHSCSADissertation title: Role of negative elongation factor in regulation of gene expression and breast cancer Progression. Dr. Sun graduated from the Molecular Medicine Program in May 2009 and is currently a postdoctoral fellow in the laboratory of Dr. Fernando Camargo, Department of Stem Cell and Rengerative Medicine, Harvard University, MA.

01/2007 – 11/2008 Ning Ding UTHSCSA*Committee ChairDissertation title: Mediator Links Epigenetic Silencing of Neuronal Gne Expression with X-linked Mental

12

Retardation. Dr. Ding was a Ph.D. student under my mentorship. Dr. Ding graduated from the Molecular Medicine Program in December 2008, completed a postdoctoral fellowship under Dr. Ronald Evans, Department of Developmental Biology at The Salk Institute in La Jolla, CA, and is currently a Principal Scientist at Genentech, Inc., San Francisco, CA.

09/2007 – 07/2010 AndreAna Pena UTHSCSA Dissertation title: Dr. Pena was an IMGP Ph.D. student in the laboratory of Dr. Olivia Pereira-Smith, Department of Cellular and Structural Biology, UTHSCSA. Dr. Pena graduated from the IMGP program in December 2010.

12/2006 – 03/2008 Haiying Zhou UTHSCSA*Committee ChairDissertation title: Role of MED12/Mediator as a link between Gli3-dependent Sonic hedgehog signaling and X-linked mental retardation. Dr. Zhou was a Ph.D. student under my mentorship. Dr. Zhou graduated from the Molecular Medicine program in March 2008, completed a postdoctoral fellowship in the laboratory of Dr. Robert Tjian, Department of Molecular and Cell Biology, University of California, Berkeley, and is currently a Research Associate, Howard Hughes Medical Institute, University of California, Berkeley, CA.

08/2006 – 08/2008 Jennifer Apodaca UTHSCSADissertation title: Regulation of prion protein in yeast and mammalian cells via ubiquitin mediated degradation. Dr. Apodaca graduated from the Molecular Medicine Program in August 2008, and was currently enrolled as a Graduate Student in the Physician Assistant Program, UTHSCSA.

05/2006 – 07/2008 Chi-Sheng Lu UTHSCSADissertation title: The Role of BRCA1/BARD1 in Breast Cancer. Dr. Lu graduated from the Molecular Medicine Program in July 2008 and is currently employed in a Postdoctoral Position in the laboratory of Dr. Pao-Tien Chuang, Cardiovascular Research Institute at the University of California, San Francisco.

10/2005 – 06/2006 Wendy Bussen UTHSCSADissertation title: Mechanism and regulation of homologous recombination in human cells. Dr. Bussen graduated from the Molecular Medicine Program in July 2006, and is was employed as a Postdoctoral Fellow in the Department of Radiation Oncology-Cancer Biology at Washington University.

09/2005 – 11/2006 Mingjiu Chen UTHSCSADissertation title: Functional study to determine the role of TREX2 and TREX1 in maintaining genome integrity. Dr. Chen graduated from the Molecular Medicine Program in December 2006, and was employed as a Scientist at Abbott Laboratories in Worcester, MA.

04/2005 – Present Amy Trauernicht UTHSCSA*Committee ChairDissertation title: The role of the deleted in breast cancer-1 gene product, DBC-1, in estrogen-independent breast cancer cell survival. Dr. Trauernicht was a Ph.D student under my mentorship. Dr. Trauernicht graduated from the Molecular Medicine Program in May 2007, was employed as a postdoctoral fellow at Biogen Idec, Inc., and is currently a Field Applications Scientist Manager at Life Technologies in San Diego, California.

06/2005 – 12/2006 Seokjoong Kim UTHSCSA*Committee ChairDissertation title: The role of MED12 in WNT/-catenin signaling. Dr. Kim was a Ph.D student under my mentorship. Dr. Kim graduated from the Molecular Medicine Program in December 2006, was employed as a postdoctoral fellow in the laboratory of Dr. Jin-Soo Kim, Laboratory of Genomic Engineering, Seoul National University, South Korea, and is currently Director of Scientific Research at ToolGen, Inc. Seoul, South Korea.

13

04/2005 – 05/2007 Han Li UTHSCSADissertation title: Impact of Ku80 on Genomic Stability, Cancer and Ageing. Dr. Li graduated from the Molecular Medicine Program in May 2007 and was currently employed as a Postdoctoral Fellow, in the laboratory of Dr. Serrano in Madrid, Spain.

05/2004 – 05/2006 Teresa Marple UTHSCSADissertation title: BRCA2 and BLM have Opposing Functions in Response to DNA Damaging Agents and in the Maintenance of Mouse Major Satellite Repeat DNA. Dr. Marple graduated from the Molecular Medicine Program in May 2006 and was currently employed in the Department of Pathology, Center for Comparative Medicine at the University of California, Davis.

07/2004 – 04/2006 Bingnan Gu UTHSCSADissertation title: The roles of CTIP in the maintenance of genome stability and control of cell differentiation. Dr. Gu graduated from the Molecular Medicine Program in May 2006, and was employed as a Postdoctoral Scholar in the laboratory of Dr. Maller, Department of Biological Chemistry at the University of California, Irvine.

03/2005 – 02/2006 Horng-Ru Lin UTHSCSADissertation title: Cyclin-Dependent Kinase Inhibitor Regulation During DNA Replication Initiation in Xenopus. Dr. Lin graduated from the Molecular Medicine Program in March 2006 and is currently employed as a Postdoctoral Fellow in the laboratory of Dr. Don Ganem, Department of Microbiology & Immunology at the University of California, San Francisco. 03/2003 – 03/2005 Wei Tan UTHSCSA*Committee ChairDissertation title: Coordinate transcription control by ZBRK1 and BRCA1. Dr. Tan was a Ph.D student under my mentorship. Dr. Tan graduated from the Molecular Medicine program in March 2005, completed a successful postdoctoral fellowship in the laboratory of Dr. Michael Karin, Department of Pharmacology, University of California, San Diego School of Medicine, and now is currently employed as a Senior Research Scientist in the Oncology Research Unit at Pfizer, San Diego, California.

09/2003 – 06/2004 Teresa Motycka UTHSCSADissertation title: Role of Rad52 in DNA double strand break repair. Dr. Motycka graduated from the Molecular Medicine Program in July 2004, and is currently employed at Johnson and Johnson in Union City, California.

12/2001 – 06/2003 Karen Block UTHSCSADissertation title: CDC34 Regulation and Its Role in Vertebrate DNA Replication Initiation. Dr. Block graduated from the Molecular Medicine Program in August 2003 and is currently employed as an Associate Professor/Research in the Department of Medicine-Division of Nephrology, UTHSCSA.

06/2001 – 04/2002 Jill Gilroy UTHSCSADissertation title: Role of Platelet-derived Growth Factor Receptor Beta Signaling in Kidney Development. Dr. Gilroy graduated from the Molecular Medicine Program in May 2002. Dr. Gilroy was appointed as a Postdoctoral Fellow at UC San Diego.

10/2000 – 04/2001 Linda deGraffenried UTHSCSADissertation title: Identification of Transcription Factors Regulating Estrogen Receptora Gene Transcription. Dr. deGraffenried was a Ph.D. student in the laboratory of Dr. Susanne Fuqua, Department of Molecular Medicine, UTHSCSA. Dr. deGraffenried graduated in 2001 and is currently an Associate Professor, Human Development & Family Sciences at the University of Texas, Austin.

04/2000 – 11/2000 Qing Zhong UTHSCSADissertation title: The biological function of breast cancer susceptibility genes in DNA damage response

14

and repair. Dr. Zhong was a Ph.D. student in the laboratory of Dr. Wen-Hwa Lee, Department of Molecular Medicine, UTHSCSA. Dr. Zhong graduate in 2000 and is currently an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, TX.

Ph.D. Dissertations Directed (Total number of students: 15)


05/2018 – Present Ross Shamby UTHSCSADissertation title: To be determined. Mr. Shamby is a first year IBMS Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA.

05/2018 – Present Thu-Minh Duong UTHSCSADissertation title: SHH/GLI3 signaling axis a therapeutic target in SPOP-mutant castration resistant prostate cancer. Ms. Duong is a second year IBMS Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA.

05/2011 – 05/2017 Minju Park UTHSCSADissertation title: The molecular basis of Mediator subunit MED12 in the pathogenesis of uterine fibroids. Dr. Park was a Molecular Medicine Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Park is currently a postdoctoral fellow at Rockefeller University.

05/2012 – 04/2016 Alison D. Clark UTHSCSADissertation title: Mediator kinase module as a transducer of oncogenic Wnt/-catenin signaling. Dr. Clark was an IMGP Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Clark graduated in 2016 and is currently a postdoctoral fellow at UTHSCSA.

06/2009 – 12/2014 Fangjian Gao UTHSCSADissertation title: Mediator is a transducer of Sox17 signaling in definitive endoderm development. Mr. Gao was a Molecular Medicine Ph.D. student under my mentorship, Department of Molecular Medicine, UTHSCSA. Dr. Gao graduated from the Molecular Medicine Program in December 2014, and is currently a postdoctoral fellow in the laboratory of Dr. Diana Hargreaves, Laboratory of Molecular and Cell Biology, Salk Institute, La Jolla, CA.

07/2009 – 11/2012 Nam Hee Kim UTHSCSADissertation title: Mediator and epigenetic control of neuronal gene expression and neural progenitor cell identity. Dr. Kim was a Ph.D. student under my mentorship. Dr. Kim graduated from the Molecular Medicine Program in May 2013, and is currently a Principal Research Scientist at ImmunoActiva, San Diego, CA.

06/2006 – 04/2012 Jason Spaeth UTHSCSADissertation title: Molecular determinants and pathological disruption of a MED12-Cyclin C interface in Mediator. Dr. Spaeth was a Ph.D. student under my mentorship. Dr. Spaeth graduated from the Molecular Medicine program in April 2012 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Roland Stein, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.

04/2008 – 06/2012 Shoujun Gu UTHSCSADissertation title: Basic helix-loop-helix protein Twist1 represses Sox9 in chondrogenesis. Dr. Gu was a Ph.D. student under my mentorship. Dr. Gu graduated from the Molecular Medicine program in June 2012 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Yingzi Yang, Genetic Disease Research Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland.

04/2005 – 07/2011 Xuan Xu UTHSCSADissertation title: Mediator is a transducer of amyloid- precursor protein-dependent nuclear signaling. Dr. Xu was a Ph.D. student under my mentorship. Dr. Xu graduated from the Molecular Medicine program in

15

July 2011 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Ying E. Zhang, Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland.

04/2008 – 07/2011 SeJin Kim UTHSCSADissertation title: the role of DBC-1 in the modulation of cellular stress responses. Dr. Kim was a Ph.D. student under my mentorship. Dr. Kim graduated from the Molecular Medicine program in July 2011 and is currently employed as a postdoctoral fellow in the laboratory of Dr. Jeffrey M. Rosen, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

01/2007 – 11/2008 Ning Ding UTHSCSADissertation title: Mediator Links Epigenetic Silencing of Neuronal Gne Expression with X-linked Mental Retardation. Dr. Ding was a Ph.D. student under my mentorship. Dr. Ding graduated from the Molecular Medicine Program in December 2008, completed a postdoctoral fellowship under Dr. Ronald Evans, Department of Developmental Biology at The Salk Institute in La Jolla, CA, and is currently a Principal Scientist at Genentech, Inc., San Francisco, CA.

12/2006 – 03/2008 Haiying Zhou UTHSCSADissertation title: Role of MED12/Mediator as a link between Gli3-dependent Sonic hedgehog signaling and X-linked mental retardation. Dr. Zhou was a Ph.D. student under my mentorship. Dr. Zhou graduated from the Molecular Medicine program in March 2008, completed a postdoctoral fellowship in the laboratory of Dr. Robert Tjian, Department of Molecular and Cell Biology, University of California, Berkeley, and is currently a Research Associate, Howard Hughes Medical Institute, University of California, Berkeley, CA.

06/2005 – 05/2007 Amy Trauernicht UTHSCSADissertation title: The role of the deleted in breast cancer-1 gene product, DBC-1, in estrogen-independent breast cancer cell survival. Dr. Trauernicht was a Ph.D student under my mentorship. Dr. Trauernicht graduated from the Molecular Medicine Program in May 2007, was employed as a postdoctoral fellow at Biogen Idec, Inc., and is currently a Field Applications Scientist Manager at Life Technologies in San Diego, California.

06/2005 – 12/2006 Seokjoong Kim UTHSCSADissertation title: The role of MED12 in WNT/-catenin signaling. Dr. Kim was a Ph.D student under my mentorship. Dr. Kim graduated from the Molecular Medicine Program in December 2006, was employed as a postdoctoral fellow in the laboratory of Dr. Jin-Soo Kim, Laboratory of Genomic Engineering, Seoul National University, South Korea, and is Director of Scientific Research at ToolGen, Inc. Seoul, South Korea.

05/2000 – 03/2005 Wei Tan UTHSCSADissertation title: Coordinate transcription control by ZBRK1 and BRCA1. Dr. Tan was a Ph.D student under my mentorship. Dr. Tan graduated from the Molecular Medicine program in March 2005, completed a successful postdoctoral fellowship in the laboratory of Dr. Michael Karin, Department of Pharmacology, University of California, San Diego School of Medicine, and now is currently employed as a Senior Research Scientist in the Oncology Research Unit at Pfizer, San Diego, California.

Post-Doctoral/Instructor Trainee Supervision (Total number of trainees: 14)


01/2018 – Present Suba Muralimanoharan UTHSCSA

16

Supervised research carried out by Dr. Suba Muralimanoharan, Instructor, Department of Molecular Medicine, which is to isolate, characterize, and determine the pathogenic role of human uterine fibroid stem cells.

01/2017 – Present Lindsey Barron-Myers UTHSCSASupervised postdoctoral research carried out by Dr. Lindsey Barron-Myers, which is to characterize the role of Mediator-associated CDK8/19 in the regulation of super-enhancer function and colon cancer cell biology.

01/2017 – Present Hailian Shen UTHSCSASupervised postdoctoral research carried out by Dr. Hailian Shen, which is to characterize the epigenomic landscape of uterine fibroid subtypes.

09/2017 – 04/2018 Tuomas Heikkinen University of HelsinkiSupervised postdoctoral research carried out by Dr. Tuomas Heikkinen, which was to investigate precision targeting of MED12-mutant chronic lymphocytic leukemia with NOTCH inhibitors. Dr. Heikkinen was a visiting postdoctoral fellow from the University of Helsinki.

09/2014 – 07/2016 Marieke Oldenbroek UTHSCSASupervised postdoctoral research carried out by Dr. Marieke Oldenbroek, which is to characterize the role of the GLI3-dependent Sonic Hedgehog signaling axis as a potential therapeutic target in castration resistant prostate cancer.

04/2016 – 09/2016 Alison Clark UTHSCSASupervised postdoctoral research carried out by Dr. Alison Clark, which was to characterize the role of the Mediator kinase module as a transducer of oncogenic Wnt/-catenin signaling. Dr. Clark is currently an IRACDA fellow in the laboratory of Dr. Susan Mooberry at UTHSCA.

12/2014 – 1/2016 Fangjian Gao UTHSCSASupervised postdoctoral research carried out by Dr. Fangjian Gao, which was to characterize the role of the Mediator subunit MED12 as a transducer of Sox17 signaling in definitive endoderm development. Dr. Gao is currently postdoctoral fellow in the laboratory of Dr. Diana Hargreaves, Laboratory of Molecular and Cell Biology, Salk Institute, La Jolla, CA.

11/2012 – 10/2015 Nam Hee Kim UTHSCSASupervised postdoctoral research carried out by Dr. Nam Hee Kim, which was to characterize the role of the Mediator subunit MED12 in the pathogenesis of uterine fibroids. Dr. Kim is currently investigating permanent postdoctoral fellowship opportunities.

04/2012 – 12/2012 Jason Spaeth UTHSCSASupervised postdoctoral research carried out by Dr. Jason Spaeth, which was to characterize the role of the Mediator subunit MED12 in the pathogenesis of uterine fibroids. Dr. Spaeth is currently employed as a postdoctoral fellow in the laboratory of Dr. Roland Stein, Department of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee.

10/2011 – 04/2012 SeJin Kim UTHSCSASupervised postdoctoral research carried out by Dr. SeJin Kim, which was to characterize the role of the deleted in breast cancer-1 gene product, DBC-1, in the modulation of cellular stress responses. Dr. Kim currently employed as a postdoctoral fellow in the laboratory of Dr. Jeffrey M. Rosen, Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.

10/2011 – 03/2012 Xuan Xu UTHSCSASupervised postdoctoral research carried out by Dr. Xuan Xu, which was to investigate the role of the Mediator subunit MED12 a transducer of amyloid- precursor protein-dependent nuclear signaling. Dr. Xu

17

is currently employed as a postdoctoral fellow in the laboratory of Dr. Ying E. Zhang, Laboratory of Cellular and Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland.

03/2008 – 08/2008 Haiying Zhou UTHSCSASupervised postdoctoral research carried out by Dr. Haiying Zhou, which was to study the role of Mediator as a link between GLI3-dependent Sonic Hedgehog signaling and intellectual disability disorders. Dr. Zhou went on to complete a second postdoctoral fellowship in the laboratory of Dr. Robert Tjian, Department of Molecular and Cell Biology, University of California, Berkeley, and is currently a Research Associate, Howard Hughes Medical Institute, University of California, Berkeley, CA.

05/2007 – 09/2007 Amy Trauernicht UTHSCSASupervised postdoctoral research carried out by Dr. Amy Trauernicht, which was to characterize the role of the deleted in breast cancer-1 gene product, DBC-1, in estrogen-independent breast cancer cell survival. Dr. Trauernicht went on to a second postdoctoral fellowship at Biogen IDEC, and is currently a Field Applications Scientist Manager at Life Technologies in San Diego, California.

01/2003 – 12/2003 Stefan Sigurdsson UTHSCSASupervised postdoctoral research carried out by Dr. Sigurddson, which was to characterize the physical and functional interaction between the key homologous recombination proteins RAD51 and RAD54. Dr. Sigurddson examined the influence of RAD51 on the biochemical activities of RAD54, including ATPase activity and DNA topological changes and D-loop formation. Dr. Sigurddson went on to serve as a postdoctoral fellow in the laboratory of Dr. Jesper Svejstrup, Gene Transcription Laboratory, London Research Institute and Clare Hall Laboratories, London, England.

Pre-Doctoral Student Supervision (Total number of students: 1)


05/2001 – 04/2002 Linh Ngo UTHSCSASupervised the work of Ms. Ngo, who was a Ph.D. student in training. Ms. Ngo was studying the role of the breast and ovarian tumor suppressor BRCA1 in the modulation of progesterone receptor function. Ms. Ngo withdrew from the Molecular Medicine program in April 2003 to pursue her M.B.A. Ms. Ngo is currently employed as an analyst at Accenture, Houston, Texas.

Medical Student Supervision (Total number of students: 3)


06/2017 – 12/2017 Zachary Coates UTHSCSA

07/2017 – Present Alexander Oderhowho UTHSCSA

07/2017 – Present Meahwish Imdad UTHSCSA

Rotation Student Supervision (Total number of students: 54)


03/2018 – 04/2018 Thu Minh Duong UTHSCSASupervised the rotation project of Ms. Duong, who aimed to examine the impact of SHH/GLI pathway disruptors on the androgen-independent growth of prostate cancer cell lines harboring oncogenic mutations in the E3 ubiquitin ligase SPOP. These targeted mutations, generated by CRISPR/Cas9-mediated genome editing, disrupt SPOP-mediated turnover of GLI3, leading to hyperactivated SHH signaling and enhanced androgen-independent prostate cancer cell growth.

18

11/2017 – 12/2017 Abdulhafiz Imam UTHSCSASupervised the rotation project of Mr. Imam, who aimed to examine the impact of Mediator kinase disruption on the regulation of super-enhancer function and gene regulation in colorectal cancer cells. Mr. Imam characterized gene expression changes in MED12 exon 2-disruped cells that bear defective Mediator-associated CDK8/19 kinas activity.

10/2017 – 11/2017 Courtney Johnson UTHSCSASupervised the rotation project of Ms. Johnson, who sought to investigate the occurrence of pathological R-loop accumulation in human uterine fibroid tissues bearing mutations in the driver oncogene MED12.

08/2017 – 09/2017 Ross Shamby UTHSCSASupervised the rotation project of Mr. Shamby, who aimed to examine the impact of Mediator kinase disruption on the regulation of super-enhancer function and gene regulation in colorectal cancer cells. Mr. Shamby performed ChIP-qPCR analyses in colorectal cancer cell lines bearing a MED12 exon 2 disrupted allele to validate alterations the in super-enhancer landscape.

10/2016 – 11/2016 Laura Avena UTHSCSASupervised the rotation project of Ms. Avena, who sought to characterize prostate cancer cell lines harboring oncogenic mutations in the E3 ubiquitin ligase SPOP. These targeted mutations, generated by CRISPR/Cas9-mediated genome editing, disrupt SPOP-mediated turnover of GLI3, leading to hyperactivated SHH signaling and enhanced androgen-independent prostate cancer cell growth. Ms. Avena undertook to validate gene expression changes in paired SPOP WT and mutant prostate cancer cells uncovered by prior RNA-seq analyses.

08/2016 – 09/2016 Thu Minh Duong UTHSCSASupervised the rotation project of Ms. Duong, who sought to comparatively analyze Mediator-associated CDK8/19 kinase activity in human uterine fibroid tissues bearing WT or exon 2 mutations in the RNA polymerase II transcriptional Mediator subunit MED12.

11/2015 – 12/2015 Alex Chu UTHSCSASupervised the rotation project of Mr. Chu, who aimed to characterize prostate cancer cell lines harboring oncogenic mutations in the E3 ubiquitin ligase SPOP. These targeted mutations, generated by CRISPR/Cas9-mediated genome editing, disrupt SPOP-mediated turnover of GLI3, leading to hyperactivated SHH signaling and enhanced androgen-independent prostate cancer cell growth. Mr. Chu undertook molecular and biological phenotyping of clonal cell lines harboring these mutations.

08/2015 – 09/2015 Liesl Lawrence UTHSCSASupervised the rotation project of Ms. Khoogar, which was to characterize colorectal cancer cell lines harboring a targeted deletion of exon 2 within the gene encoding Mediator subunit MED12. This targeted deletion generated by CRISPR/Cas9-mediated genome editing removes the -catenin binding domain within MED12, and Ms. Lawrence undertook molecular and biological phenotyping of clonal cell lines for defects in Wnt-catenin-dependent ongogenic signaling.

03/2013 – 05/2013 Roxanne Khoogar UTHSCSASupervised the rotation project of Ms. Khoogar, which was to examine the functional interaction between Mediator subunit MED12 and Sox17, a regulator of endodermal cell fate. Ms. Khoogar sought to map the reciprocal binding domains on each protein and also to examine the functional requirement for MED12 in Sox17-dependent transcription through the use of transient reporter-based assays.

09/2012 – 12/2012 Kunhua Qin UTHSCSASupervised the rotation project of Mr. Qin, which involved in vitro screening of structure-based inhibitors of Cyclin C-CDK8 kinase. Mr. Qin sought to empirically narrow a list of 35 potentially inhibitory scaffolds identified through a prior structure-based approach in the laboratory using in vitro kinase and protein-binding assays.

19

03/2012 – 05/2012 Xiaojie Yu UTHSCSASupervised the rotation project of Mr. Yu, which was to examine the role of the Mediator subunit MED12 in neural progenitor cell (NPC) biology. Mr Yu sought to functionally validate findings derived from prior global transcriptomic profiling that implicated MED12 in control of cell adhesion and cell cycle gene expression programs. To this end, Mr. Yu employed MED12 knockdown in NPCs coupled with cell adhesion assays and FACS analyses.

09/2012 – 11/2012 Yuen Fang UTHSCSASupervised the rotation project of Ms. Fang, which was to examine the impact of uterine leiomyoma-linked mutations in the Mediator subunit MED12 on Mediator associated Cyclin C-CDK8 kinase activity. Ms. Fang sought to examine the impact of MED12 mutations on its ability to anchor and activate Cyclin C-CDK8 in Mediator using in vitro and in vivo binding and kinase assays.

03/2012 – 05/2012 Bo Li UTHSCSASupervised the rotation project of Mr. Li, which was to assist a senior graduate student in chromatin immunoprecipitation-deep sequencing (ChIP-seq) studies designed to identify global genome-wide interactions between Mediator and the Amyloid- Precursor Protein (APP) intracellular domain (AICD).

01/2012 – 03/2012 Alison Doyungan UTHSCSASupervised the rotation project of Ms. Doyungan, which was to screen inhibitors of Mediator-associated Cyclin C-CDK8 kinase. Ms. Doyungan sought to empirically narrow a list of predicted kinase inhibitors identified through a virtual ligand screen of the NCI diversity compound library using a combination of in vitro kinase and binding assays using recombinant baculovirus expressed kinase subunits. Ms. Doyungan joined my laboratory on a permanent basis in May 2012.

09/2011 – 11/2011 Leizl Francisco UTHSCSASupervised the rotation project of Ms. Francisco, which was to study inhibitors of Mediator-associated Cyclin C-CDK8 kinase. Ms. Francisco sought to examine the mechanism of inhibition of kinase inhibitors using in vitro binding and other biochemical methods.

10/2011 – 11/2011 Calais Williams UTHSCSASupervised the rotation project of Ms. Williams, which was to study role of the Mediator subunit MED12 in neural progenitor cell (NPC) biology. Ms. Williams sought to validate results obtained from global gene expression profiling analyses in MED12-knockdown NPCs.

09/2011 – 12/2011 Mosharrof Mondhal UTHSCSASupervised the rotation project of Mr. Mondhal, which was to study role of the Mediator subunit MED12 as a transducer of Amyloid- Precursor Protein (APP)-dependent nuclear signaling. Mr. Mondahl sought to identify functional interactions between Mediator and the APP intracellular domain (AICD) by chromatin immunoprecipitation analyses.

03/2011 – 05/2011 Minju Park UTHSCSASupervised the rotation project of Mr. Park, which was to study the impact of uterine leiomyoma-linked mutations in MED12 on Mediator associated Cyclin C-CDK8 kinase activity. Mr. Kim sought to examine Mediator-associated kinase activity from WT and MED12 mutant uterine leiomyomas. Mr. Kim joined my laboratory as a permanent member in May 2011.

01/2010 – 03/2010 Xin Bao UTHSCSASupervised the rotation project of Ms. Bao, which was to study the regulation of Gli3-dependent Sonic hedgehog signaling by the Mediator kinase module. Ms. Bao sought to examine the impact of X-linked intellectual disability mutations in the Mediator subunit MED12 on constraint of Gli3 transactivation activity.

09/2009 – 11/2009 Izhar Batth UTHSCSA

20

Supervised the rotation project of Mr. Batth, which was to study the basis for regulation of CycC-CDK8 by MED12 within the RNA Pol II transcriptional Mediator. Mr. Batth sought to identify through directed mutagenesis of surface amino acid residues on CycC a suspected MED12-bdining regulatory pocket.

03/2009 – 05/2009 Fangjian Gao UTHSCSASupervised the rotation project of Mr. Gao, which was to investigate the role of the RNA polymerase II Mediator as a biochemical link between histone methylation and ubiquitylation in epigenetic silencing of neuronal gene expression. Mr. Gao joined my laboratory as a permanent member in May 2009.

03/2009 – 05/2009 Cristina Rohena UTHSCSASupervised the rotation project of Ms. Rohen, an IMGP Student, which was to study the role of the RNA polymerase II transcriptional Mediator subunit MED12 in neural progenitor cell maintenance. Ms. Rohena specifically undertook to investigate the role of MED12 in neural progenitor cell proliferation.

08/2008 – 12/2008 Vitnary Choe UTHSCSASupervised the rotation project of Ms. Choe, which was to investigate the role of the RNA polymerase II transcriptional Mediator in suppression of Gli3-dependent Sonic hedgehog signaling. Ms. Choe sought to identify, through combined biochemical and genetic approaches, the binding surface on Gli3 specific for the MED12, through which Gli3 specifically interfaces with Mediator.

09/2008 – 11/2008 Anne Porter UTHSCSASupervised the rotation project of Ms. Anne Porter, IMGP Student, which was to investigate the status of Gli3-dependent Sonic hedgehog signaling in cell lines derived from patients afflicted with FG and Lujan syndromes, X-linked mental retardation disorders arising from missense mutations in the RNA polymerase II transcriptional Mediator subunit MED12, a Gli3 target subunit in Mediator.

01/2008 – 03/2008 Jun Ho Ko UTHSCSASupervised the rotation project of Mr. Ko, which was to study the role of the RNA polymerase II transcriptional Mediator as a transducer of Amyloid-beta Precursor Protein (APP)-dependent nuclear signaling. Mr. Ko sought to examine the impact of Mediator subunit MED12 depletion through RNA interference on the transactivation function of APP.

08/2007 – 12/2007 Balaji Parameswaran UTHSCSASupervised the rotation project of Mr. Parameswaran, which was to examine the functional interaction between the deleted in breast cancer 1 gene product, DBC1, and estrogen receptor-alpha in hormone-independent breast cancer cell survival.

08/2006 – 12/2006 Jiangyan Zhu UTHSCSASupervised the rotation project of Ms. Zhu, which was to study the physical and functional interaction between the MED12 interface in the RNA polymerase II transcriptional Mediator and G9a histone methyltransferase in neuronal gene silencing.

03/2006 – 05/2006 Dong-Hyun Kim UTHSCSASupervised the rotation project of Mr. Kim, which involved a chemical genetics approach to study cellular substrates of CDK8/CyclinC, a CDK/Cyclin pair within the multisubunit RNA polymerase II transcriptional Mediator that is associated with transcriptional repression. Mr. Kim sought to generate mutant CDK8 derivatives with altered specificity for a specific ATP nucleotide analog.

03/2006 – 05/2006 Nam Hee Kim UTHSCSASupervised the rotation project of Ms. Kim, which was to study the role of the breast and ovarian tumor suppressor BRCA1 and the deleted in breast cancer 1 gene product DBC1 in breast cancer cell proliferation and survival. Ms. Kim sought to engineer human breast cancer cell lines supporting both constitutive and inducible knockdown of BRCA1 and DBC-1 through the use of RNA interference technologies. Ms. Kim joined my laboratory as a permanent member in May 2006.

21

01/2006 – 03/2006 Jungmi Ahn UTHSCSASupervised the rotation project of Ms. Ahn, which was to study the potential functional interaction between the MED12 subunit in the RNA polymerase II transcriptional Mediator and Gli2, a downstream effector and transcriptional regulator in the Sonic hedgehog signaling pathway.

01/2006 – 03/2006 Jason Spaeth UTHSCSASupervised the rotation project of Mr. Spaeth, which was to study the biological role and regulation of the RNA polymerase II transcriptional Mediator. Mr. Spaeth sought to engineer, using retroviral-mediated gene transfer, mammalian cell lines stably expressing individual epitope-tagged Mediator subunits. Mr. Spaeth joined my laboratory as a permanent member in May 2006.

08/2005 – 12/2005 Junchao Dong UTHSCSASupervised the rotation project of Mr. Dong, which was to investigate the role of the RNA polymerase II transcriptional Mediator subunits CDK8/CyclinC as a potential physiological kinase for the stress responsive transcription factor Activating Transcription Factor 4 (ATF-4).

08/2005 – 12/2005 Richard Tamfu UTHSCSASupervised the rotation project of Mr. Tamfu, which was to study the role of BRCA1 as a ligand-independent transcriptional repressor of the estrogen receptor. Mr. Tamfu participated in a proteomics-based search involving biochemical fractionation of cell extracts and subsequent mass spectrometric analysis for the identification of BRCA1-containing estrogen receptor-alpha protein complexes.

03/2005 – 05/2005 SeJin Kim UTHSCSASupervised the rotation project of Ms. Kim, which was to study the biological function of the deleted in breast cancer 1 gene product, DBC1. Toward this objective, Ms. Kim sought to engineer human cervical carcinoma cell lines stably expressing an epitope-tagged DBC1 derivative to facilitate biochemical purification and proteomics analysis of DBC1-interacting proteins. Ms. Kim joined my laboratory as a permanent member in May 2005.

01/2005 – 03/2005 David New UTHSCSASupervised the rotation project of Mr. New, which was to investigate the role of the breast and ovarian tumor suppressor BRCA1 in ligand-independent transcriptional repression of the estrogen receptor-alpha. Mr. New used small scale gene expression profiling analyses in human breast cancer cells to monitor changes in hormone-independent expression levels of estrogen receptor-alpha target genes following targeted reduction of BRCA1 by RNA interference.

01/2005 – 03/2005 Xuan Xu UTHSCSASupervised the rotation project of Ms. Xu, which was to study the role of the RNA polymerase II transcriptional Mediator as a transducer of Amyloid-beta Precursor Protein (APP)-dependent nuclear signaling. As the first individual in the laboratory to initiate this project, Ms. Xu’s efforts were directed toward physical mapping of the reciprocal binding domains on both APP and MED12, the APP interface in Mediator. Ms. Xu joined my laboratory as a permanent member in May 2005.

08/2004 – 12/2004 Lavinia Dumitrache UTHSCSASupervised the rotation project of Ms. Dumitrache, which was to study the role of the RNA polymerase II transcriptional Mediator as a transducer of Wnt/beta-catenin signaling. Ms. Dumitrache sought to examine the impact of Mediator subunit MED12 overexpression on the transactivation function of beta-catenin.

08/2004 – 12/2004 Priyadharshini Narayan UTHSCSASupervised the rotation project of Ms. Narayanan, which was to study the role of the RNA polymerase II transcriptional Mediator as a negative regulator of Gli3-dependent SHH signaling. Ms. Narayanan sought to define conditions for reproducible knockdown of the Mediator subunit MED12 and thereafter examine the impact MED12 knockdown on the transactivation function of Sonic hedgehog-stimulated Gli3.

22

03/2004 – 05/2004 Ji-Hyun Oum UTHSCSASupervised the rotation project of Ms. Oum, which was to study the physical interaction between the RNA polymerase II transcriptional Mediator subunit MED12 and G9a histone methyltransferase. Ms. Oum sought to validate an in vivo interaction between MED12 and G9a and to map their reciprocal interaction surfaces through biochemical-based protein interaction assays in vitro.

01/2004 – 03/2004 Ning Ding UTHSCSASupervised the rotation project of Mr. Ding, who sought to investigate the role of the breast and ovarian tumor suppressor BRCA1 as a ligand-independent suppressor of estrogen receptor-alpha transcriptional activity. Mr. Ding joined my laboratory as a permanent member in May 2004, and successfully defended his Ph.D. thesis in November 2008.

08/2003 – 12/2003 Rajeswari Sankaran UTHSCSASupervised the rotation project of Ms. Sankaran, which was to study the role of the RNA polymerase II transcriptional Mediator as a negative regulator of Gli3-dependent Sonic hedgehog signaling. Ms. Narayanan sought to establish conditions for reproducible transient knockdown of the RNA polymerase II transcriptional Mediator subunit and thereafter examine the impact MED12 knockdown on the transactivation function of Sonic hedgehog-stimulated Gli3.

03/2003 – 05/2003 Angelina Hoefle UTHSCSASupervised the rotation project of Ms. Hoefle, which was to study the function and regulation of the RNA polymerase II transcriptional Mediator. Ms Hoefle sought express in and purify from E. Coli recombinant Mediator subunits for purposes of antibody production and in vitro functional analyses.

01/2003 – 03/2003 Justin Voorhees UTHSCSASupervised the rotation project of Mr. Voorhees, which was to characterize the function of the breast and ovarian tumor suppressor BRCA1 in ligand-independent transcriptional repression of the estrogen receptor-alpha. In this regard, Mr. Voorhees sought to engineer an estrogen receptor-expressing recombinant adenovirus for purposes of repression complex purification. In addition, Mr. Voorheess undertook to construct and characterize BRCA1-expressing baculoviruses for purposes of biochemical characterization of BRCA1.

01/2003 – 03/2003 Ching-Shyi Wu UTHSCSASupervised the rotation project of Mr. Wu, which was to characterize the physical and functional interaction between ZBRK1, transcriptional repressor of DNA damage response genes, and its direct interaction partner and corepressor BRCA1, the breast and ovarian tumor suppressor. Mr. Wu undertook to engineer and express ZBRK1 deletion and point mutations for purposes of fine mapping of the BRCA1 interaction surface on ZBRK1 and for evaluating the influence of BRCA1 on the DNA-binding activity of ZBRK1.

08/2002 – 12/2002 Yu Wang UTHSCSASupervised the rotation project of Mr. Wang, which was to characterize the physical and functional interaction between ZBRK1, a BRCA1-dependent transcriptional repressor of DNA damage response genes, and VprBP, a cellular E3 ubiquitin ligase and ZBRK1-interacting protein. Mr. Wang sought to identify through in vitro protein interaction studies the reciprocal binding surfaces on ZBRK1 and VprBP.

03/2002 – 05/2002 Bingnan Gu UTHSCSASupervised the rotation project of Mr. Gu, which was to characterize the physical and functional interactions of two transcriptional corepressors, NCoR and CtIP, with ZBRK1, a BRCA1-dependent transcriptional repressor of DNA damage response genes. Mr. Gu performed in vitro protein interaction mapping studies and in vivo transient repression assays to examine the functional interactions between these proteins in ZBRK1-imposed transcriptional repression.

03/2002 – 05/2002 Changhyun Seong UTHSCSA

23

Supervised the rotation project of Mr. Seong, which was to examine the role of the breast and ovarian tumor suppressor BRCA1 in ligand-independent transcriptional repression of the estrogen receptor-alpha. Mr. Seong sought to identify ligand-independent estrogen receptor-interacting protein complexes from breast cancer cell lines using immobilized protein interaction affinity chromatography and subsequent mass spectrometry.

01/2002 – 03/2002 Amy Trauernicht UTHSCSASupervised the rotation project of Mr. Seong, which was to examine the role of the breast and ovarian tumor suppressor BRCA1 in ligand-independent transcriptional repression of the estrogen receptor-alpha. Ms. Trauernicht pioneered this project in the laboratory and her initial efforts were aimed at evaluating the influence of BRCA1 on estrogen receptor dimerization and DNA-binding activities. Ms. Trauernicht joined my laboratory as a permanent member in May 2002, and successfully defended her Ph.D. thesis in May 2007.

08/2001 – 12/2001 Seokjoong Kim UTHSCSASupervised the rotation project of Mr. Kim, which was to study the biological role and regulation of the RNA polymerase II transcriptional Mediator. Mr. Kim initiated these studies in the laboratory and his initial efforts in this regard were involved in generating mammalian cell lines stably expressing epitope-tagged Mediator subunits for Mediator complex purification, expressing recombinant Mediator subunits for antibody production purposes, and construction of a yeast two-hybrid screening platform for highthrougput analysis of individual Mediator subunits. Mr. Kim joined my laboratory as a permanent member in May 2002, and successfully defended his Ph.D. thesis in December 2006.

03/2001 – 05/2001 Michelle Bromhal UTHSCSASupervised the rotation project of Ms. Bromhal, which was to biochemically characterize ZBRK1, a BRCA1-dependent transcriptional repressor of DNA damage response genes. Ms. Bromhal sought to engineer a ZBRK1-expressing baculovirus and produce quantities of recombinant ZBRK1 in insect cells sufficient for biochemical analysis of its sequence-specific DNA-binding activity.

01/2001 – 03/2001 Linh Ngo UTHSCSASupervised the rotation project of Ms. Ngo, which was to examine the role of the breast and ovarian tumor suppressor BRCA1 in ligand-independent transcriptional repression of the estrogen receptor-alpha. Ms. Ngo undertook to assess the impact of BRCA1 mutations on ligand-independent activation of endogenous estrogen receptor target genes. Ms. Ngo joined my laboratory as a permanent member in May 2001, and withdrew from the Molecular Medicine Graduate Program in April 2003.

08/2000 – 12/2000 Dal Latsha UTHSCSASupervised the rotation project of Mr. Latsha, which was to biochemically characterize ZBRK1, a BRCA1-dependent transcriptional repressor of DNA damage response genes. Mr Latsha sought to engineer, express, and purify a recombinant fragment of ZBRK1 to facilitate subsequent biochemical purification and identification of ZBRK1-interacting proteins using immobilized protein affinity chromatography and mass spectrometry.

01/2000 – 03/2000 Kevin Wyatt McMahon UTHSCSASupervised the rotation project of Mr. McMahon, which was to biochemically characterize the breast and ovarian tumor suppressor BRCA1. Mr. McMahon sought to engineer sought to engineer WT and familial breast cancer derived mutant BRCA1-expressing baculoviruses and produce quantities of recombinant BRCA1 derivatives in insect cells sufficient for biochemical analyses.

08/1999 – 12/1999 Wei Tan UTHSCSASupervised the rotation project of Mr. Tan, which was to characterize ZBRK1, a BRCA1-dependent transcriptional repressor of DNA damage response genes. Mr. Tan, who initiated this project in the laboratory, used directed mutagenesis to identify the DNA- and BRCA1-binding domains on ZBRK1. Mr. Tan joined my laboratory as a permanent member in May 2000, and successfully defended his Ph.D. thesis in March2009.

24

Undergraduate Student Supervision (Total number of students: 6)


06/2017 – 08/2017 Jose Huergo UTHSCSASupervised the research project of Mr. Huergo, an undergraduate student from St. Mary’s University (San Antonio, Texas) who participated in UTHSCSA CURE Program. Mr. Huergo sought to disrupt super-enhancer in colorectal cancer cell lines using the CRISPR/Cas9 genome editing system. Mr. Huergo is currently in his senior year at St. Mary’s and he is planning to pursue further training in medical school.

06/2005 – 08/2005 Amy Wollish UTHSCSASupervised the research project of Ms. Wollish, an undergraduate student from Bucknell University (Lewisburg, Pennsylvania) who participated in our Summer Undergraduate Research Fellowship Program. Ms. Wollish sought to investigate a potential physical and functional interaction between the MED12 subunit in the RNA polymerase II transcriptional Mediator and Gli2, a downstream effector and transcriptional regulator in the Sonic hedgehog signaling pathway. Ms. Wollish is currently a Ph.D. student under Dr. Mark Heise in the Department of Genetics, University of North Carolina School of Medicne.

06/2004 – 08/2004 Claire Gordon UTHSCSASupervised the research project of Ms. Gordon, an undergraduate student from Rice University (Houston, Texas), who participated in our Summer Undergraduate Research Fellowship Program. Ms. Gordon sought to investigate the role of the breast and ovarian tumor suppressor BRCA1 as a ligand-independent transcriptional repressor of the estrogen receptor-.

06/2003 – 08/2003 Charlene Fajardo UTHSCSASupervised the research project of Ms. Fajardo, an undergraduate student from Chaminade University (Honolulu, Hawaii), who participated in our Summer Undergraduate Research Fellowship Program. Ms. Fajardo sought to investigate the biochemical basis of the breast and ovarian tumor suppressor BRCA1 as a transcriptional coregulator of the DNA damage responsive gene repressor ZBRK1.

06/2000 – 08/2000 Marcie Hannemann UTHSCSASupervised the research project of Ms. Hannemann, an undergraduate student from Trinity University (San Antonio, Texas), who participated in our Summer Undergraduate Research Fellowship Program. Ms. Hannemann sought to biochemically characterize the DNA-binding activity of the BRCA1-dependent transcriptional repressor ZBRK1.

06/1999 – 08/1999 Mark Lessner UTHSCSASupervised the research project of Mr. Lessner, an undergraduate student from Trinity, who participated in our Summer Undergraduate Research Fellowship Program. Mr. Lessner sought to produce for future biochemical analyses recombinant BRCA1 protein in insect cells using a baculovirus expression system.

RESEARCH

EXPERTISE:

Hormonal Tumorigenesis and Therapeutic Resistance Molecular basis of Mediator subunit 12 (MED12) in the pathogenesis of uterine fibroids SHH signaling and castration resistant prostate cancer

25

DBC-1 and estrogen signaling in endocrine resistant breast cancer Control of estrogen signaling by the breast tumor suppressor BRCA1

Genetic and Epigenetic Regulation of Neural Development and Disease Mediator and epigenetic control of neuronal gene expression and differentiation Mediator and the molecular basis of syndromal X-linked intellectual disability Mediator as a transducer of Amyloid-Precursor Protein signaling in Alzheimer’s Disease

PROJECTS:

1. Molecular basis of MED12 in the pathogenesis of uterine fibroidsSupported by NIH award 1R01 HD087417Uterine leiomyomas (LM; fibroids) are monoclonal neoplasms of the myometrium (MM) and represent the most frequent tumors in women worldwide. Although benign, they nonetheless account for significant gynecologic and reproductive dysfunction. As no long-term non-invasive treatment option exists for LM, deeper insight regarding tumor etiology is key to the development of newer targeted therapies. Accordingly, our studies suggest an etiologic basis for the predominant LM subtype and further offers proof of concept for therapeutic intervention involving new druggable targets in this specific genetic setting. LM arise from the genetic transformation of a single MM stem cell (SC) into a tumor initiating cell (LM SC) that seeds and sustains fibroid growth through asymmetric cell divisions. Heretofore, the dominant drivers of cell transformation have been largely identified. THE most prevalent among these, accounting for ~70% of LM, are recurrent somatic mutations in the gene encoding the MED12 subunit of Mediator, a multiprotein signal processor through which regulatory information conveyed by gene-specific transcription factors is transduced to RNA polymerase II (Pol II). However, the impact of these mutations on MED12 function and the molecular basis for their tumorigenic potential remain unknown. Herein, we show that LM-linked mutations in MED12 disrupt its ability to activate Cyclin C (CycC)-dependent kinase 8 (CDK8) in Mediator, leading to reduced site-specific RNA Pol II phosphorylation and global gene dysregulation. We also identify genetic programs uniquely dysregulated in MED12-mutant fibroids, leading us to hypothesize that Mediator kinase disruption as a consequence of MED12 mutations elicits transcriptional reprogramming and altered signaling sufficient to drive MM SC transformation. We further hypothesize that MED12-mutant LM are therapeutically susceptible to reactivation of CDK8 or pharmacologic modulation of uniquely dysregulated signaling pathways. To test these hypotheses we will: (1) Establish the pathogenic role of Mediator kinase disruption in MED12-mutant LM. We will ask if genetic or chemical disruption of CDK8 (or its paralog CDK19) in Mediator can induce fibrotic transformation of MM SCs and, conversely, if WT MED12 can restore CDK8/19 kinase activity and suppress the fibrotic phenotype of MED12-mutant LM SCs; (2) Elucidate the pathogenic mechanism of Mediator kinase disruption in MED12-mutant LM. We will define the biochemical basis by which MED12 mutations disrupt CycC-CDK8/19 kinase activity and employ an integrated genome-scale approach to acquire the unique transcriptomic and epigenomic profiles of MED12 WT and mutant LM SCs; (3) Examine the therapeutic implications of Mediator kinase disruption in MED12-mutant LM. We will ask if reactivation of CDK8/19 or pharmacologic manipulation of signaling pathways uniquely dysregulated in MED12-mutant LM SCs can reverse their fibrotic phenotype. We expect these studies to significantly impact personalized treatment of women with LM.

2. Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroidsSupported by NIH award 1R01 HD094378Uterine fibroids (UFs; leiomyomas) are the most important benign neoplastic threat to women’s health worldwide, but disproportionately affect women of color, particularly African American (AA) women, who have a threefold higher incidence rate and relative risk of UFs than Caucasian (CC) women. While the

26

underlying cause for this risk disparity is not fully understood, recent studies implicate hypovitaminosis D as a major contributor. Thus, AA women have a tenfold increased risk of vitamin D deficiency compared to CC women, and as we first reported, UF risk is inversely correlated with 25-hydroxy vitamin D serum levels. Nonetheless, it is not clear whether and how the processes that drive UF formation and determine relative risk are genetically or biochemically linked. In this regard, we and others have identified somatic mutations in the transcriptional Mediator subunit MED12 as the dominant drivers of UFs, accounting for ~70% of tumors. Notably, MED12-mutant UFs are characterized by significant chromosomal loss and rearrangement, suggesting genomic instability as a driving force in tumor progression. Herein, we clarify the molecular basis for mutant MED12- driven genomic instability, and further identify vitamin D3 receptor signaling as a likely suppressor of this process. We show that MED12-mutant UF stem cells (SCs) accumulate high levels of unrepaired DNA doublestrand breaks (DSBs) through downregulation of key DNA damage response (DDR) and repair genes. Notably, we find the vitamin D3/receptor axis to be a variable modulator of MED12-regulated DDR gene expression. Thus, we show that reduced vitamin D3/receptor signaling suppresses, while elevated signaling activates, DDR genes downregulated in MED12-mutant UF SCs. Based on these findings, we hypothesize that hypovitaminosis D exacerbates DNA damage accumulation and genomic instability arising in MED12-mutant UFs, leading to enhanced tumor progression and burden. Accordingly, we propose that vitamin D3, through reparation of an impaired DDR will provide therapeutic benefit in MED12-mutant tumors. To test these hypotheses, we will (1) Elucidate the molecular basis of genomic instability in MED12-mutant UFs. We will determine if DSB accumulation in MED12-mutant UF SCs derives from defects in DNA damage-induced checkpoint signaling and repair and/or R-loop-induced replication stress. (2) Investigate the relationship between vitamin D3 and MED12 in UF genome maintenance. We will ask whether and how vitamin D3 signaling strength modulates the DDR defects in MED12-mutant UF SCs, relate this activity to patient race and serum vitamin D levels, and elucidate the mechanism by which the vitamin D3/receptor axis and MED12 coordinately control the DDR network at the genomic and epigenomic levels; (3) Examine the therapeutic potential of vitamin D3 in a preclinical mouse model of human UFs. Using a renal capsule mouse model of human UFs, we will evaluate vitamin D3 and its potent non-hypercalcemic analogs for therapeutic efficacy, safety, and mechanism of action, including impact on tumor DNA damage load and DDR gene networks.

3. SHH/GLI3 signaling axis as a therapeutic target in SPOP mutant CRPCSupported by prior CPRIT award RP140435Although localized prostate cancer is highly curable, more than 32,000 US men succumb annually to metastatic disease. Androgen deprivation therapy results in rapid responses in men with metastatic prostate cancer, but most eventually progress to lethal castration resistant prostate cancer (CRPC) characterized by androgen receptor (AR)-dependent tumor growth despite castrate levels of circulating androgens. Thus, a compelling need exists to develop effective treatments and address resistance mechanisms in men with advanced prostate cancer. Our studies suggest a rational basis to explain the development of CRPC in a molecular subtype that approaches 10-15% of prostate cancers, and offers proof of concept in a pre-clinical model for treatment of CRPC in this specific genetic setting. In this regard, the Sonic hedgehog (SHH) pathway, an essential signaling axis in prostate development and homeostasis, is implicated in prostate cancer progression and therapeutic resistance. Recent work has shown that androgen deprivation induces SHH signaling, which reciprocally activates AR-dependent gene expression and prostate cancer cell growth leading to CRPC. We propose that this scenario is particularly germane to a prostate cancer subtype supporting hyperactivated SHH signaling through mutations in the tumor suppressor SPOP. Recurrent somatic mutations in SPOP are the most frequent non-synonymous mutations in prostate cancer, occurring in 10-15% of cases, and appear to anchor a distinct genetic subtype. Herein, we show that SPOP, an E3 ubiquitin ligase substrate-binding subunit, targets GLI3, a transcriptional effector of SHH, for ubiquitin-mediated proteosomal turnover, and notably, that SPOP-mediated GLI3 degradation is abrogated by oncogenic mutations in SPOP. Furthermore, we show that pathologically stabilized GLI3 in SPOP-mutant prostate cancer cells interacts with AR to reestablish an AR signaling axis leading to rapid acquisition of androgen-independent oncogenic growth. We thus hypothesize that hyperactivated GLI3-dependent SHH signaling drives androgen-independent growth of SPOP-mutant tumors through a mechanism involving reactivation of AR-driven gene expression. Accordingly, we propose that FDA-approved SHH pathway inhibitors and AR-GLI3 binding disruptors will block progression to CRPC in this prostate cancer subtype. To confirm and extend this hypothesis, we will: (1) Elucidate the mechanism by which SHH-activated GLI3 promotes androgen-independent growth of SPOP mutant

27

prostate cancer cells. We will employ an integrated genome-scale approach to understand how crosstalk between GLI3 and AR promotes androgen-independent growth of SPOP-mutant prostate cancer cells. Using ChIP-seq in SPOP WT and mutant LNCaP cells, we will acquire androgen-dependent and androgen-independent GLI3/AR cistromic and corresponding epigenomic profiles. When integrated with corresponding RNA-seq data, these profiling efforts will permit us to correlate mutant SPOP-dependent changes in gene expression with alterations in the composition and epigenetic status of the GLI3/AR cistromes, providing unprecedented insight into how transcriptional programs are pathologically rewired by mutant SPOP as a course of androgen independence; (2) Investigate the impact of SHH pathway disruption on the development of castration resistant SPOP mutant tumors in a preclinical mouse model. We will investigate whether the FDA-approved SHH pathway inhibitor vismodegib will reduce the frequency at which SPOP-mutant prostate tumor xenografts progress to androgen-independence in castrate mice. In addition, we will assess the preclinical efficacy of a novel class of AR-GLI3 disruptors (AGDs) identified herein from a virtual ligand screen of the Broad Institute Drug Repurposing Library. Because we hypothesize that hyperactivated SHH signaling drives castration resistant growth of SPOP-mutant tumors, we predict that vismodegib and AGDs will produce a pharmocodynamically effective response in this model. Confirmation of these findings will inform the clinical use and development of SHH pathway inhibitors for precision treatment of CRPCs harboring SPOP mutations; (3) Determine if SHH/GLI3 signaling predicts clinical aggressiveness in SPOP mutant prostate tumors. We will conduct a prospective clinical observation study to follow the course of advanced prostate cancer patients (both SPOP mutation positive and negative) enrolled at the initiation of androgen deprivation therapy (ADT). SHH/GLI3 pathway activation will be correlated with SPOP mutation status in circulating tumor cells of PSA recurrent patients to determine whether SPOP mutations predict SHH-driven castration resistance. Our goal is to identify the specific subset of patients harboring SPOP mutant tumors who might benefit from the use of SHH/GLI3 inhibitors at the time of ADT, as dual therapy is likely to be more effective before as opposed to after castration resistance is achieved.

4. Mediator as a transducer of amyloid precursor protein-dependent nuclear signalingSupported by prior NIH award 1R21 AG051962Alzheimer’s disease (AD) is a profoundly debilitating neurodegenerative disorder without effective treatment or determinative antemortem diagnostics. Improvements in diagnostic and treatment options will require a better understanding of the biological processes that drive AD onset and progression. The prevailing model to explain AD pathogenesis holds that neuronal degeneration and clinical demise are precipitated by the gradual accumulation, in brain centers controlling memory and cognition, of amyloid- (A) peptide, a catabolite of the transmembrane Amyloid Precursor Protein (APP). However, recent studies suggest a complex etiology for AD, particularly for its idiopathic late-onset variety, that may involve the contribution of amyloid-independent mechanisms. Amyloidogenic processing of APP into A concurrently liberates a small APP intracellular domain (AICD) that enters the nucleus and induces the expression of genes implicated in AD pathology. Although amyloid-independent, this APP-dependent signaling pathway is nonetheless tightly linked to A production, suggesting that pathologic accumulation of A, as occurs in AD, could be paralleled by an increase in concentration-dependent AICD-mediated target gene induction. Accordingly, AICD-target genes could represent both early biological indicators of A-induced pathology as well as functional effectors of amyloid-independent pathogenic triggers. Enhanced mechanistic insight into AICD-mediated transcription control could identify new therapeutic targets and candidate markers for AD. In this regard, we recently discovered that the AICD activates transcription by targeting MED12, an RNA polymerase II transcriptional Mediator subunit implicated in human cognitive development. To identify downstream effectors of Mediator-dependent APP nuclear signaling, we profiled the transcriptomes of mouse neural progenitors following depletion of APP or MED12. Our data reveal a significant contribution of Mediator to AICD-dependent transcription control genome-wide, and further implicate the AICD and Mediator in the coordinate upregulation of neural genes in the hippocampus of AD patients compared to controls. We therefore hypothesize that the AICD and Mediator coordinately regulate a neural gene network with direct relevance to AD pathology. To confirm an extend this hypothesis, we propose to: (1) Elucidate the mechanistic basis for coordinate transcriptional control by AICD and Mediator. We will combine RNAi-mediated APP and MED12 depletion with ChIP-exo/seq to render high resolution genome-wide binding profiles for the AICD and its Mediator-dependent epigenetic imprint; (2) Determine the correlative relationship between Mediator-dependent AICD-target gene expression and AD severity. We will investigate pathologic changes in AICD-target gene expression as a course of AD using histologically

28

staged postmortem brain tissues from AD patients and an established mouse model of AD. Statistical analyses will be used to establish whether AICD-target gene expression may be correlated with disease severity. We expect these studies to have important basic and translational implications for AD. 5. Molecular basis of Mediator in the etiology of syndromal X-linked intellectual disabilitySupported by prior NIH awards 1R01 MH085320 and 1R01 AR053100X-linked intellectual disability (XLID) affects 1–2 of every 1,000 males and accounts for ∼10% of all intellectual disability (ID). Approximately one-third of XLID cases are associated with sufficiently coincident somatic, neurobehavioral, or metabolic features to permit diagnostic designation and are therefore classified as “syndromal” in nature. To date, more than 140 syndromal XLID conditions have been identified, almost half of which are attributable to mutations in single genes. The identification of these genes has been a dominant force in linking syndromes previously considered separate entities based on clinical criteria alone. Notable among the XLID syndromes so linked are FG (or Opitz-Kaveggia) syndrome and Lujan (or Lujan-Fryns) syndrome which arise from different missense mutations in the Xq13 gene encoding MED12, a subunit of the RNA polymerase II transcriptional Mediator. In addition to ID, FG and Lujan syndromes share several overlapping clinical manifestations, including agenesis/dysgenesis of the corpus callosum, macrocephaly, hypotonia, distinct craniofacial dysmorphisms, seizures, and behavioral disturbances. Our long-term goal is to decipher the molecular mechanisms by which mutations in MED12 elicit ID as well as the broad spectrum of overlapping and unique clinical phenotypes associated with these allelic disorders. In this regard, we showed that FG/R961W and Lujan/N1007S missense mutations in MED12 disrupt epigenetic repression of neuronal gene expression imposed by the RE1 silencer transcription factor (REST; also known as neuron restrictive silencer factor, NRSF), a master regulator of neuronal fate. In this regard, we discovered a protein interaction network required for REST-directed neuronal gene silencing comprising REST, Mediator, and G9a histone methyltransferase, a dominant euchromatic histone 3-lysine 9 (H3K9) mono- and di-methylase in mammalian cells. We showed that the MED12 interface in Mediator links REST with G9a-dependent histone H3K9 dimethylation to suppress neuronal genes in nonneuronal cells. Importantly, we found that the FG and Lujan mutations in MED12 disrupt its REST corepressor function through impaired recruitment of Mediator to RE1 (REST repressor) elements. Impaired recruitment of Mediator, an essential link between RE1-bound REST and G9a, leads to reduced G9a recruitment, diminished levels of G9a-dependent H3K9me2, and derepression of REST target gene expression. Together, these findings implicate Mediator in epigenetic restriction of neuronal gene expression to the nervous system and suggest a pathologic basis for MED12-associated XLID involving impaired REST-dependent neuronal gene regulation.

More recently, we reported that the FG and Lujan mutations in MED12 disrupt a Mediator-imposed constraint on GLI3-dependent Sonic Hedgehog (SHH) signaling. In this regard, it is notable that several phenotypes associated with FG and/or Lujan syndromes including macrocephaly, corpus callosal defects, hypertolerism, syndactyly, and cognitive impairment, overlap with a subset of those variously appearing in Greig cephalopolysyndactyly syndrome (GCPS) and/or Pallister-Hall syndrome (PHS) arising from mutations in GLI3, a Sonic Hedgehog (SHH) signaling effector that we had previously shown physically and functionally interacts with MED12. Given the physical and functional interaction between GLI3 and MED12 coupled with the fact that mutations in each of these interacting proteins elicit congenital anomaly syndromes with overlapping phenotypes, we hypothesized, and recently confirmed, that pathogenic mutations in MED12 leading to FG and Lujan syndromes elicit dysregulated GLI3-dependent SHH signaling. We showed that the FG/R961W and Lujan/N1007S mutations disrupt the gene-specific association of MED12 with CDK8, an additional Mediator subunit that we identified to be a suppressor of GLI3 transactivation activity. In FG/R961W and Lujan/N1007S patient-derived cells, we documented enhanced SHH pathway activation and GLI3-target gene induction coincident with impaired recruitment of CDK8 onto promoters of GLI3-target genes, but not non–GLI3-target genes. Our findings that XLID mutations in MED12 elicit aberrant GLI3-dependent SHH signaling not only suggest an additional basis for cognitive dysfunction through altered brain development, but may further explain a broad range of clinically diverse non-CNS phenotypes associated with these syndromal disorders, including digit, craniofacial, corpus callosal, and anorectal malformations. Collectively, these findings suggest that dysregulated GLI3-dependent SHH signaling contributes to phenotypes of individuals with FG and Lujan syndromes and further reveal a basis for the gene-specific manifestation of pathogenic mutations in a global transcriptional coregulator.

29

Dysregulation of the REST and SHH pathways as a consequence of XLID mutations in MED12 could impact neuronal differentiation and function, since both pathways have been implicated in neural progenitor cell (NPC) maintenance. Specifically, REST has been implicated in the regulation of genes that promote neuronal differentiation and migration, while SHH is an established mitogen that stimulates NPC proliferation and cell cycle kinetics. Notably, we have recently implicated MED12 in the maintenance of neural stem cell identity, and we are currently exploring whether and how MED12/Mediator modulates REST- and SHH-dependent gene expression programs in this process. We expect these studies to have important human health implications for cell replacement therapy in neurological disease as well as the etiology of XLID.

PUBLICATIONS: (*indicates Peer Reviewed)

Abstracts (partial list)

1. Clark, A.D., Oldenbroek, M., Spaeth, J., Gao, F., and Boyer, T.G. (2015) Mediator Kinase Module as a Transducer of Oncogenic Wnt/β-catenin signaling. 2015 American Society for Cell Biology Annual Meeting, San Diego, CA.

2. Oldenbroek, M. and Boyer, T.G. (2015) SPOP modulates GLI3-dependent SHH signaling in androgen independent prostate cancer. 2015 American Society for Cell Biology Annual Meeting, San Diego, CA. USA

3. Pereira, B., Thiele, M., Gao, F., Boyer, T.G., and Schrewe, H. (2015) MED12 modulates Sox17 transcriptional activity in early mouse development. 2015 EMBO Workshop: Embryonic-Extraembryonic Interfaces, Gottingen, Germany.

4. Oldenbroek M, Deng J, Sun L, Boyer TG. (2015) SPOP modulates GLI3-dependent SHH signaling in androgen independent prostate cancer. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

5. Clark, A.D., Oldenbroek, M., Spaeth, J., and Boyer, T.G. (2015) Mediator Kinase Module as a Transducer of Oncogenic Wnt/β-catenin signaling. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

6. Clark, A.D., Oldenbroek, M., Spaeth, J., and Boyer, T.G. (2015) Mediator Kinase Module as a Transducer of Oncogenic Wnt/β-catenin signaling. UTHSCSA Dental Science Symposium, San Antonio, TX.

7. Oldenbroek M, Deng J, Sun L, Boyer TG. (2015) SPOP modulates GLI3-dependent SHH signaling in androgen independent prostate cancer. Third Annual San Antonio Postdoctoral Research Forum, San Antonio, TX.

8. Oldenbroek M, Deng J, Sun L, Boyer TG. (2015) SPOP modulates GLI3-dependent SHH signaling in androgen independent prostate cancer. Joint Annual NCI T32/CPRIT Retreat, San Antonio, TX.

9. Turunen, M., Spaeth, J.M, Keskitalo, S., Park, M.J., Kivioja, T., Clark, A.D., Makinen, N., Gao, F., Vaharautio, A., Aavlkko, M., Kampjarvi, K., Nurkkala, H., Vahteristo, P., Kim, C.A., Aaltonen, L.A., Varjosalo, M., Taipaile, J., and Boyer, T.G. (2014) Uterine-leiomyoma-linked MED12 mutations disrupt Mediator-associated CDK activity. Keystone Symposium 2014: Transcriptional Regulation/Cancer Epigenetics, Santa Fe, NM.

10. Clark, A.D., Oldenbroek, M., Spaeth, J., Gao, F., and Boyer, T.G. (2014) Mediator Kinase Module as a Transducer of Oncogenic Wnt/β-catenin signaling. 2014 American Society for Cell Biology Annual Meeting, Philadelphia, PA.

30

11. Clark, A.D., Oldenbroek, M., Spaeth, J., Gao, F., and Boyer, T.G. (2014) Mediator Kinase Module as a Transducer of Oncogenic Wnt/β-catenin signaling. 2014 Experimental Biology Annual Meeting, Philadelphia, PA.

12. Oldenbroek M, Deng J, Sun L, Boyer TG. (2014) Prostate cancer-associated mutations in SPOP Stabilize GLI3, a critical determinant of androgen-independent prostate cancer cell growth. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

13. Clark, A.D., Oldenbroek, M., Spaeth, J., Gao, F., and Boyer, T.G. (2014) Mediator Kinase Module is a Transducer of Oncogenic Wnt/β-catenin signaling. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

14. Clark, A.D., Spaeth, J., Gao, F., Tomita, Y., and Boyer, T.G. (2014) The MED12/Cyclin C Interface as a Therapeutic Target in Oncogenic Wnt/β-catenin signaling. UTHSCSA Dental Science Symposium, San Antonio, TX.

15. Oldenbroek M, Deng J, Sun L, Boyer TG. (2014) Prostate cancer-associated mutations in SPOP Stabilize GLI3, a critical determinant of androgen-independent prostate cancer cell growth. Joint Annual NCI T32/CPRIT Retreat, San Antonio, TX.

16. Spaeth, J.M and Boyer, T.G. (2013) Mediator Kinase Module is a Transducer of Oncogenic Wnt/β-catenin signaling and a potential therapeutic target in colorectal cancer. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

17. Xu, X., Kim, N.H., Spaeth, J.M., Livi, C., and Boyer, T.G. (2012) Mediator as a transducer of amyloid precursor protein-dependent nuclear signaling. Zing Neurodegeneration Conference, Xcaret, Mexico.

18. Kim, N.H., Livi, C. B., and Boyer, T.G. (2012) Global contribution of MED12 to neural stem cell identity. Center for Biomedical Neuroscience Annual Retreat, San Antonio, TX.

19. Doyungan, A., Spaeth, J., Tomita, Y., and Boyer, T.G. (2012) Novel Structure-Based Inhibitors of Wnt/β-catenin axis. UTHSCSA Cancer Therapy & Research Center Annual Symposium, San Antonio, TX.

20. Kim, N.H., Livi, C. B., and Boyer, T.G. (2012) Global contribution of MED12 to neural stem cell identity. Lost Pines Conference: Genetics and Epigenetics of Genome Integrity, Smithville, TX.

21. Ding, N., Zhou, H., Kim, S., Shinkai, Y., and Boyer, T.G. (2007) Mediator requirement for epigenetic silencing of neuronal gene expression. Salk Institute Symposium on Biological Complexity: Diseases of Transcription. San Diego, CA.

22. Trauernicht, A.M. and Boyer, T.G. (2006) Modulation of human estrogen receptor alpha (ER) function by the product of the deleted in breast cancer 1 gene, DBC-1. 2006 Keystone Symposia, Regulation of Eukaryotic Transcription: From Chromatin to mRNA, Taos, NM.

23. Kim, S., Hecht, A., and Boyer, T.G. (2006) Mediator is a transducer of Wnt/-catenin signaling. 2006 Keystone Symposia, Regulation of Eukaryotic Transcription: From Chromatin to mRNA, Taos, NM.

24. Sharp, Z.D., Tan, W., Boyer, T.G., and Mancini, M.A. (2005) Nuclear dynamics of BRCA1-dependent transcription regulation. Era of Hope, Department of Defense Breast Cancer Research Program Meeting, Philadelphia, PA.

31

25. Boyer, T.G. and Trauernicht, A.M. (2005) Modulation of human estrogen receptor alpha function by BRCA1. Era of Hope, Department of Defense Breast Cancer Research Program Meeting. Philadelphia, PA. Platform presentation.

26. Boyer, T.G., Tan, W., and Kim, S. (2005) Coordinate transcription control by BRCA1 and the KRAB-Zinc finger protein ZBRK1. Era of Hope, Department of Defense Breast Cancer Research Program Meeting. Philadelphia, PA.

27. Trauernicht, A.M. and Boyer, T.G. (2004) Modulation of human estrogen receptor alpha (ER) function by BRCA1. Nuclear Hormone Receptors. Keystone Symposia, Keystone, Colorado.

28. Tan, W. Zheng, L., Chen, P.-L., Lee, W.-H., and Boyer, T.G. (2003) Molecular dissection of a BRCA1-dependent transcriptional repression domain. Mechanisms of Eukaryotic Transcription. Cold Spring Harbor, New York.

29. Bromhal, M., Tan, W., Boyer, T.G., and Yew, P.R. (2002) The role of BRCA1-dependent ubiquitination in breast cancer. Era of Hope, Department of Defense Breast Cancer Research Program Meeting. Orlando, Florida.

30. Block, K.L., Boyer, T.G., and Yew, P.R. (2002) Characterization of the human CDC34 protein complex that complements DNA replication in CDC34-depleted Xenopus egg extracts. International Symposium on Cancer Research. Frontiers in Cancer Research: A Molecular Perspective, San Antonio, Texas.

31. Ngo, L. and Boyer, T.G. (2002) Mediator as a co-activator of the human progesterone receptor . International Symposium on Cancer Research. Frontiers in Cancer Research: A Molecular Perspective, San Antonio, Texas.

32. Tan, W., Zheng, L., Chen, P.-L., Lee, W.-H., and Boyer, T.G. (2002) Mechanistic basis of BRCA1-mediated sequence-specific transcriptional repression. International Symposium on Cancer Research. Frontiers in Cancer Research: A Molecular Perspective. San Antonio, Texas.

33. Boyer, T.G., Zheng, L., Annab, L.A., Afshari, C.A., and Lee, W.-H. (2002) Modulation of estrogen receptor function by BRCA1. Era of Hope, Department of Defense Breast Cancer Research Program Meeting. Orlando, Florida. Platform presentation.

34. Block, K.L., Boyer, T.G., and Yew, P.R. (2002) Phosphorylation of the human ubiquitin conjugating enzyme, CDC34, by casein kinase 2. The First International Conference: Ubiquitin, Ubiquitin-like Proteins, and Cancer, Houston, Texas.

35. Boyer, T.G., Martin, M.E.D., Wang, G., Cantin, G., Lees, E., Ricciaridi, and Berk, A.J. (1999) Mammalian Srb/mediator complex is targeted by adenovirus E1A CR3 through a metazoan-specific subunit. Mechanisms of Eukaryotic Transcritpion. Cold Spring Harbor, New York. Platform presentation.

36. Boyer, T.G., Ricciardi, R.P., Rickert, P., Lees, E., and Berk, A.J. (1998) Target of Ad2 E1A CR3 Activation Domain. 1998 Molecular Biology Small DNA Tumor Viruses Meeting, Madison, Wisconsin. Platform presentation.

37. Berk, A.J., Boyer, T.G., Kobayashi, N., Surby, M., Triezenberg, S.J., Horn, P.J., Sullivan, S.M., Stevens, J., Ricciardi, R.P., Rickert, P., and Lees, E. (1998) Activation by Viral Activators. LXIII Cold Spring Harbor Symposium on Quantitative Biology: Mechanisms of Transcription, Cold Spring Harbor, New York.

32

38. Boyer, T.G., Ricciardi, R.P., and Berk, A.J. (1997) A Novel Coactivator of Adenovirus E1A Conserved Region 3-Mediated Transactivation. 1997 American Cancer Society Senior Postdoctoral Fellows Meeting, Riverside, CA. Platform presentation.

39. Berk, A.J., Kobayashi, N., Brown, H., Martel, L., Martin, M., Boyer, T.G.,Triezenberg, S., Horn, P., and Sullivan, S. (1997) Mechanisms of Viral Activators and Repressors. Mechanisms of Eukaryotic Transcription, Cold Spring Harbor, New York.

40. Boyer, T.G., Ricciardi, R.P., and Berk, A.J. (1997) A Novel Coactivator of Adenovirus E1A Transactivation. Mechanisms of Eukaryotic Transcription, Cold Spring Harbor, New York.

41. Berk, A.J., Bryant, G.O., Boyer, T.G., and Kobayashi, N. (1995) Interactions of Activation Domains with General Transcription Factors and Coactivators. Mechanisms of Eukaryotic Transcription, Cold Spring Harbor, New York.

42. Kobayashi, N., Boyer, T.G., and Berk, A.J. (1995) Interactions of Activation Domains with TFIIA. Mechanisms of Eukaryotic Transcription, Cold Spring Harbor, New York.

43. Boyer, T.G., Ebright, R.H., and Berk, A.J. (1995) Mechanistic Studies of Adenovirus E1A Transactivation. ICRF 1995 Tumour Virus Meeting on Papovaviruses, Papillomavirus, and Adenoviruses, Cambridge, England. Platform presentation.

44. Boyer, T.G. and Berk, A.J. (1994) Functional interactions of general transcription factors and coactivators with Adenovirus E1A Conserved Region 3. Molecular Biology of SV40, Polyoma, and Adenoviruses, Cold Spring Harbor, New York. Platform presentation.

45. Boyer, T.G., and Berk, A.J. (1993) Functional Interaction of the Adenovirus E1A transcriptional activation domain with holo-TFIID. ICRF 1993 Tumour Virus Meeting on Papovaviruses, Papillomavirus, and Adenovirus, Cambridge, England. Platform presentation.

46. Boyer, T.G., and Berk, A.J. (1992) In Vitro Transcriptional Stimulation by Adenovirus E1A. Molecular Biology of SV40, Polyoma, and Adenoviruses, Cold Spring Harbor, New York.

47. Boyer, T.G., and Maquat, L.E. (1988) Transcriptional Regulation of the Housekeeping Gene for Human Triosephosphate Isomerase. UCLA Symposium: DNA-Protein Interactions in Transcription; Keystone, Colorado.

Editorials and Reviews

1.* Boyer, T.G. (2017) There will be blood: hematopoiesis control by Mediator subunit MED12. Stem Cell Investig 4:4 PMID: 28217706

2.* Boyer, T. G. (2016) Transcriptional kinases: Less is more (or less). Nat Chem Biol 12, 4-5. PMID: 26820714

3.* Clark, A.D., Oldenbroek, M., and Boyer, T.G. (2015) Mediator kinase module and human tumorigenesis. Crit Rev Biochem Mol Biol 50: 393-426. PMID: 26182352

4.* Spaeth, J.M., Kim, N.H., and Boyer T.G. (2011) Mediator and human disease. Semin Cell Dev Biol 22: 776-787. PMID: 21840410

5.* Trauernicht, A.M. and Boyer, T.G. (2003) BRCA1 and estrogen signaling in breast cancer. Breast Dis 18: 11-20. PMID: 15687685

33

6.* Boyer, T.G. and Lee, W.-H. (2002) Breast Cancer Susceptibility Genes. Science and Medicine 8: 138-149.

7.* Lee, W.-H. and Boyer, T.G. (2003) BRCA1 and BRCA2 in breast cancer. Lancet 358:S5. PMID: 11784554.

8.* Boyer, T.G., Chen, P.L., and Lee, W.H. (2001) Genome mining for human cancer genes: wherefore art thou? Trends Mol Med 7: 187-189. PMID: 11325617

9.* Zheng, L., Li, S., Boyer, T.G., and Lee, W.H. (2000) Lessons learned from BRCA1 and BRCA2. Oncogene 19: 6159-6175. PMID: 11156530

Journal Articles

1.* El Andaloussi, A., Al-hendy, A., Ismail, N., Boyer, T.G., and Halder, S.K. (2018) Introduction of somatic mutation in MED12 induces oncogenic Wnt/-catenin signaling and disrupts autophagy in human uterine smooth muscle cells. J Clin Endocrinol Metab (Under review)

2.* Cheng, D., Vermulapali, V., Lu, Y., Aoyagi, S., Fry, C., Yang, Y., Foulds, C.E., Stossi, F., Trevino, L.S., Mancini, M.A., Boyer, T.G., O’Malley, B.W., Walker, C.L., Comb, M., and Bedford, M.T. (2018) CARM1 methylates MED12 to regulate its RNA binding ability. (Under review)

3.* Park, M.J., Shen, H., Kim, N.H., Gao, F., Failor, C. Knudtson, J.F., McLaughlin, J., Halder, S.K., Heikkinen, T.A., Vahteristo, P., Al-Hendy, A., Schenken, R.S., and Boyer, T.G. (2018) Mediator kinase disruption in MED12-mutant uterine fibroids from Hispanic women of South Texas. J Clin Endocrinol Metab (Under revision)

4.* Park, M.J., Shen, H., Spaeth, J.M., Tolvanven, J.H., Failor, C., Knudtson, J.F., McLaughlin, J., Halder, S.K., Yang, Q., Bulun, S.E., Al-Hendy, A., Schenken, R.S., Aaltonen, L.A., and Boyer, T.G. (2018) Oncogenic exon 22 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19. J Biol Chem 293: 4870-4882. PMID: 29440396

5.* Al-Hendy, A., Laknauer, A., Diamond, M.P., Ismail, N., Boyer, T.G., and Halder, S. (2017) Silencing MED12 gene reduces proliferation of human uterine fibroid cells mediated via Wnt/-catenin signaling pathway. Endocrinology 158: 592-603. PMID: 27967206

6.* Kim, N.H., Livi, C. B., Yew, P.R., and Boyer, T.G. (2016) Mediator subunit 12 contributes to the maintenance of neural stem cell identity. BMC Dev Biol 16: 17. PMID: 27188461

7.* Al-Hendy, A., Diamond, M.P., Boyer, T.G., and Halder, S.K. (2016) Vitamin D3 inhibits Wnt/ -catenin and mTOR signaling pathways in human uterine fibroid cells. J Clin Endocrinol Metab 101: 1542-1551. PMID: 26820714

8.* Kampjarvi, K., Kim, N.H., Keskitalo, S., Clark, A.D., von Nandelstadh, P., Turunen, M., Heikkinen, T., Park, M.J., Makinen, N., Kivinummi, K., Lintula, S., Hotakainen, K., Nevanlinna, H., Hokland, P., Bohling, T., Butzow, R., Bohm, J., Mecklin, J.P., Jarvinen, H., Kontro, M., Visakorpi, T., Taipale, J., Varjosalo, M., Boyer, T.G., and Vahteristo, P. (2016) Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. Prostate 76: 22-31. PMID: 26383637

9.* Wang, L., Zeng, H., Wang, Q., Zhao, Z., Boyer, T.G., Bian, X., and Xu, W. (2015) MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs. Sci Adv 1(9): e1500463 eCollection 2015 October PMID: 26601288

34

10.* Kampjarvi, K., Park, M.J., Mehine, M., Kim, N.H., Clark, A.D., Butzow, R., Bohling, T., Bohm, J., Mecklin, J.-P., Jarvinen, H., Tomlinson, I.P.M., van de Spuy, Z.M., Sjoberg, J., Boyer, T.G., and Vahteristo, P. (2014) Mutations in exon 1 highlight the role of MED12 in uterine leiomyomas. Hum Mut 35: 1136-1141. PMID: 24980722

11.* Turunen, M., Spaeth, J.M, Keskitalo, S., Park, M.J., Kivioja, T., Clark, A.D., Makinen, N., Gao, F., Vaharautio, A., Aavlkko, M., Kampjarvi, K., Nurkkala, H., Vahteristo, P., Kim, C.A., Aaltonen, L.A., Varjosalo, M., Taipaile, J., and Boyer, T.G. (2014) Uterine-leiomyoma-linked MED12 mutations disrupt Mediator-associated CDK activity. Cell Rep 7: 654-660. PMCID: PMC4041330

*Featured Highlight: Alderton, G.K. (2014) Transcription: Mediating tumorigenesis. Nat Rev Cancer 14: 382. PMID: 24854073

12.* Vulto-van Silfhout, A.T., de Vries, B.B, van Bon B.W., Hoischen, A., Ruiterdamp-Versteeg, M., Gilissen, C., Gao, G., van Zwam, M., Harteveld, C.L., van Essen, A.J., Hamel, B.C., Kleefstra, T., Willemsen, M.A, Yntema, H.G., van Bokhoven, H., Brunner, H.G., Boyer, T.G, and de Brouwer, A.P. (2013) Mutations in MED12 cause X-linked Ohdo syndrome. Am J Hum Genet 92: 401-406. PMCID: PMC3591845

13.* Zhou, H., Spaeth, J.M., Kim, N.H., Xu, X., Friez, M.J., Schwartz, C.E., and Boyer, T.G. (2012) MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic hedgehog signaling. Proc Natl Acad Sci, USA 109: 19763-19768. PMCID: PMC3511715

*Featured Previewed Article: Berk, A.J. (2012) Yin and yang of mediator function revealed by human mutants. Proc Natl Acad Sci, USA 109: 19519-19520 PMCID: PMC3511750

14.* Gu, S., Boyer, T.G., and Naski, M.C. (2012) Basic helix-loop-helix transcription factor twist1 inhibits the transactivator function of the master chondrogenic regulator Sox9. J Biol Chem 287: 21082-21092. PMCID: PMC3375531

15.* Krebs, P., Fan, W., Chen, Y.H., Tobita,, K., Downes, M.R., Sun, L., Li, X., Xxia, Y. Ding, N. Spaeth, J.M., Moresco, E.M. Boyer, T.G., Lo, C.W., Yen, J., Evans, R.M. and Beutler, B. 2011. Lethal mitochondrial cardiomyopathy in a hypomorphic Med30 mouse mutant is ameliorated by ketogenic diet. Proc Natl Acad Sci, US 108: 19678-82. PMCID: PMC3241770

*Featured Previewed Article: Benit, P. and Rustin, P. (2012) Changing the diet to make more mitochondria and protect the heart. Circ Res 110: 1047-1048

16.* Xu, X., Zhou, H., and Boyer T.G. (2011) Mediator is a transducer of amyloid-precursor-protein-dependent nuclear signaling. EMBO Rep12: 216-222. PMCID: PMC3059912

*Featured Previewed Article: Turner, A.J. et al. (2011) Mediator: the missing link in amyloid precursor protein signaling EMBO Rep 12: 180-181. PMCID: PMC3059916

17.* Trauernicht, A.M., Kim, S.J., Kim, N.H., Clarke, R., and Boyer, T.G. (2010) DBC-1 mediates endocrine resistant breast cancer cell survival. Cell Cycle 9: 1218-1219. PMID: 20237431

18.* Ding, N., Tomomori-Sato, C., Sato, S., Conaway, R.C., Conaway, J.W., and Boyer, T.G. (2009) MED19 and MED26 are synergistic functional targets of the RE1 silencing transcription factor in epigenetic silencing of neuronal gene expression. J Biol Chem 284: 2648-56. PMID: PMC2631966

19.* Ding, N., Zhou, H., Esteve, P.-E., Chin, H.G., Kim, S., Xu, X., Joseph, S.M., Friez, M.J., Schwartz, C.E., Pradhan, S. and Boyer, T.G. (2008) Mediator links epigenetic silencing of neuronal gene expression with X-linked mental retardation. Mol Cell 31: 347-359. PMCID: PMC2583939

35

*Featured Previewed Article: Malik, S. and Roeder, R.G. (2008) Epigenetics? Mediator does that too! Mol Cell 31: 305-306. PMID: 18691961

20.* Trauernicht, A., Kim, S.J., Kim, N.H., and Boyer, T.G. (2007) Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol 21:1526-1536. PMID: 17473282

21.* Zhou, H., Kim, S., Ishii, S., and Boyer, T.G. (2006) Mediator modulates Gli3-dependent Sonic hedgehog signaling. Mol Cell Biol 26: 8667-8682. PMCID: PMC1636813

22.* Lu, M., Chen, D., Lin, Z., Reierstad, S., Trauernicht, A.M., Boyer, T.G., and Bulun, S.E. (2006) BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. J Clin Endocrinol Metab 91: 4514-4519. PMID: 16940443

23.* Kim, S., Xu, X., Hecht, A, and Boyer, T.G. (2006) Mediator is a transducer of Wnt/-catenin signaling. J Biol Chem 281: 14066-14075. PMID: 16565090

25.* Tan, W., Kim, S., and Boyer, T.G. (2004) Tetrameric oligomerization mediates transcriptional repression by the BRCA1-dependent Kruppel-associated box-zinc finger protein ZBRK1. J Biol Chem 279: 55153-55160. PMID: 15496401

26.* Tan, W., Zheng, L., Lee, W.H., and Boyer, T.G. (2004) Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression. J Biol Chem 279: 6576-6587. PMID: 14660588

27.* Zhong, Q., Boyer, T.G., Chen, P.L., and Lee, W.H. (2002) Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res 62: 3966-3970. PMID: 12124328

28.* Block, K., Boyer, T.G., and Yew, P.R. (2001) Phosphorylation of the human ubiquitin-conjugating enzyme, CDC34, by casein kinase 2. J Biol Chem 276: 41049-41058. PMID: 11546811

29.* Zheng, L., Annab, L.A., Afshari, C.A., Lee, W.H., and Boyer, T.G. (2001) BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc Natl Acad Sci, USA 98: 9587-9592. PMCID: PMC55496

*Special Featured Article: Reynolds, T. (2001) BRCA1: lessons learned from the breast cancer gene. J Natl Cancer Inst 93: 1200-1202. PMID: 11504763

30.* Zheng, L., Pan, H., Li, S., Fleskin-Nitikin, A., Chen, P.L., Boyer, T.G., and Lee, W.H. (2000) Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell 6: 757-768. PMID: 11090615

*Featured Previewed Article: MacLachlan, T.K. and El-Deiry W.S. (2000) Pointing (zinc) fingers at BRCA1 targets. Nat Med. 6: 1318-1319. PMID: 11100109

31.* Boyer, T.G., Martin, M.E.D., Lees, E., Ricciardi, R.P., and Berk, A.J. (1999) Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature 399: 276-279. PMID: 10353252

*Featured Previewed Article: Kingston, R.E. (1999) A shared but complex bridge. Nature 399: 199-200

36

32.* Berk, A.J., Boyer, T.G., Kapandis, A.N., Ebright, R.H., Kobayashi, N.N., Horn, P.J., Sullivan, S.M., Koop, R., Surby, M.A., and Triezenberg, S.J. (1998) Mechanisms of Viral Activators. Cold Spring Harbor Symp Quant Biol 63: 243-252. PMID: 10384288

33.* Kobayashi, N., Horn, P., Sullivan, S., Triezenberg, S.J., Boyer, T.G., and Berk, A.J. (1998) DA-Complex assembly activity required for VP16C activation. Mol Cell Biol 18: 4023-4031. PMID: PMC108987

34.* Kobayashi, N., Boyer, T.G., and Berk, A.J. (1995) A class of activation domains interacts directly with TFIIA and stimulates TFIIA-TFIID-promoter complex assembly. Mol Cell Biol 15: 6465-6473. PMID: PMC230897

35.* Kerr, L.D., Ransone, L.J., Wamsley, P., Schmitt, M.J., Boyer, T.G., Zhou, Q., Berk, A.J., and Verma, I.M. (1993) Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. Nature 365: 412-419. PMID: 8413585

36.* Boyer, T.G. and Berk, A.J. (1993) Functional interaction of adenovirus E1A with holo-TFIID. Genes Dev 7: 1810-1823. PMID: 8370528

37.* Zhou, Q., Boyer, T.G., and Berk, A.J. (1993) Factors (TAFs) required for activated transcription interact with the TATA box-binding protein conserved core domain. Genes Dev 7: 180-187. PMID: 8436290

38.* Zhou, Q., Lieberman, P.M., Boyer, T.G., and Berk, A.J. (1992) Holo-TFIID supports transcriptional stimulation by diverse activators and from a TATA-less promoter. Genes Dev 6: 1964-1974. PMID: 1398073

39.* Boyer, T.G. and Maquat, L.E. (1991) Modulation of human triosephosphate isomerase gene transcription by serum. J Biol Chem 266: 13350-13354. PMID: 2071606

40.* Boyer, T.G. and Maquat, L.E. (1990) Minimal sequence and factor requirements for the initiation of transcription from an atypical, TATATAA box-containing housekeeping promoter. J Biol Chem 265: 20524-20532. PMID: 2243103

41.* Boyer, T.G., Krug, J.R., and Maquat, L.E. (1989) Transcriptional regulatory sequences of the housekeeping gene for human triosephosphate isomerase. J Biol Chem 264: 5177-5187. PMID: 2925688

PRESENTATIONS (partial list):

2018 Epigenomic landscape of uterine fibroids. Program in Cancer and Stem Cell Biology, Duke-National University of Singapore Medical School, Singapore

2017 Mediator kinase in human development and disease. Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland

2015 Molecular basis of Mediator subunit 12 in uterine leiomyomagenesis. Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX

2014 Uterine leiomyoma-linked MED12 mutations disrupt Mediator-associated CDK activity. Keystone Symposium: Transcriptional Regulation/Cancer Epigenetics, Santa Fe, NM

Mediator kinase module in human tumorigenesis. Stowers Institute for Medical Research, Kansas City, MO

37

Molecular basis of Mediator subunit 12 in the pathogenesis of uterine leiomyomas. Department of Biology, University of Texas at San Antonio, San Antonio, TX

2013 Molecular basis of Mediator subunit 12 in uterine leiomyomagenesis. Department of Biochemistry, University of California, Riverside, Riverside, CA

Mediator and the cancer connection. Department of Carcinogenesis, MD Anderson Cancer Center Science Park, Smithsvile, TX

2012 Mediator as a transducer of amyloid precursor protein-dependent nuclear signaling. Zing Neurodegeneration Conference, Xcaret, Mexico

Do MED12 mutations link prostate cancer with dysregulated GLI3-dependent Sonic Hedgehog signaling? Cancer Therapy Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX

2011 Mutations in Mediator subunit 12 link intellectual disability syndromes with dysregulated GLI3-dependent SHH signaling. Department of Cell Biology, University of Cincinnati Medical Center, Cincinnati, OH

Mediator is a transducer of amyloid precursor protein-dependent nuclear signaling. Geriatric Research, Education, and Clinical Center, South Texas Veterans Healthcare System, Audie L. Murphy VA Hospital, San Antonio, TX

2010 The REST/Mediator/G9a protein interaction network and X-linked mental retardation. PepCon-2010, Beijing, China (Invited)

2009 Mediator links epigenetic silencing of neuronal gene expression with X-linked mental retardation. Department of Cellular and Structural Biology, University of Texas Health Science Center at San Antonio, San Antonio, TX

DBC-1 as a potential therapeutic target in endocrine resistant breast cancer. Johnson and Johnson/South Texas Technology Management Inventor Interface, San Antonio, TX

2008 Epigenetic control of neuronal gene expression and neural progenitor cell fate by Mediator. New England Biolabs, Ipswich, MA. (Invited Speaker)

2006 Reciprocal modulation of human estrogen receptor function by the breast cancer associated proteins BRCA1 and DBC-1. Northwestern University, Feinberg School of Medicine, Department of Obstetrics and Gynecology, Chicago, IL

2005 Modulation of estrogen receptor survival function by the deletion in breast cancer 1 gene product DBC-1. ERA of HOPE U.S. Army Department of Defense Breast Cancer Research Program Biennial Meeting: Hormonal Signaling Section. Philadelphia, PA.

Coordinate control of DNA damage response genes by BRCA1 and the KRAB zinc finger transcriptional repressor ZBRK1. Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX

BRCA1 and sequence-specific transcription control. Barshop Institute, Department of Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX

2004 Identification and characterization of ZBRK1-interacting proteins by MALDI-TOF mass spectrometry. San Antonio Cancer Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX

38

2003 BRCA1 and sequence specific transcriptional control of DNA damage and hormone-responsive genes. Department of Genetics and Genomics, Boston University School of Medicine, Boston MA

2002 BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. ERA of HOPE U.S. Army Department of Defense Breast Cancer Research Program Biennial Meeting: Hormone signaling section, Orlando, FL

1999 Identification and functional characterization of the mammalilan mediator of RNA polymerase II transcription. Molecular Biology Institute, University of California, Los Angeles, CA

1998 Mammalian Srb/Mediator complex is targeted by Adenovirus E1A. Department of Molecular Medicine University of Texas Health Science Center at San Antonio, San Antonio, TX

1997 Biochemical purification and functional characterization of the human mediator of RNA polymerase II transcription. Department of Cell and Molecular Biology, Medical College of Georgia, Augusta, GA

A novel coactivataor of Adenovirus E1A conserved region 3-mediated transcription. American Cancer Society Senior Postdoctoral Fellows Meeting, Riverside, CA.

1995 Mechanistic studies of Adenovirus E1A transactivation. ICRF 1995 Tumour Virus Meeting on Papovaviruses, Papillomavirus, and Adenoviruses, Cambridge, UK

1994 Functional interaction of Adenovirus E1A with holo-TFIID. Department of Pharmacology University of Southern California Health Science Center, Los Angeles, CA

Mechanistic studies of Adenovirus E1A-mediated transactivation. Department of Biochemistry, University of New Hampshire, Durham, NH

Functional interaction of Adenovirus E1A with the basal RNA polymerase II transcriptional machinery. Department of Molecular Microbiology, Medical College of Wisconsin, Milwaukee, WI

Synergistic functional interactions of activation domains with basal RNA polymerase II components. Department of Biology, New York University, New York, NY

1993 Functional interaction of Adenovirus E1A transcriptional activation. ICRF 1993 Tumour Virus Meeting on Papovaviruses, Papillomavirus, and Adenovirus; Cambridge, UK

1992 In vitro transcriptional stimulation by Adenovirus E1A conserved region 3. Cold Spring Harbor; Molecular Biology of SV40, Polyoma, and Adenoviruses, Cold Spring Harbor, NY

RESEARCH GRANTS:

Federal/State - Pending

Funding Agency: NIH/NICHDGrant Number: R01 HD097734Title: MED12 mutation-induced inflammation and immunosuppression in the uterine fibroid stem cell nicheStatus: Pending IRG reviewPeriod: 12/01/2018-11/30/2023Role: PI (20%)Total Costs: $3,912,724Grant Detail: The major goals are to establish the basis, define the mechanism, and explore the clinical

39

implications of mutant MED12-induced inflammatory and immunosuppressive signaling within the UF stem cell niche.

Funding Agency: CPRITGrant Number: RP190364Title: SHH/GLI3 signaling axis as a therapeutic target in SPOP-mutant castration resistant prostate cancerStatus: Pending IRG Review Period: 0/01/2019-02/28/2022Role: PI (20%)Total Costs: $900,000Grant Detail: The major goals are to elucidate the mechanism, therapeutic vulnerability, and prognostic implications of SHH-AR crosstalk in SPOP-mutant castration resistant prostate cancer.

Federal/State – Active

Funding Agency: NIH/NICHDGrant Number: R01 HD087417Title: Molecular basis of MED12 in the pathogenesis of uterine fibroidsStatus: Active Period: 08/01/2017-04/30/2022Role: PI (20%)Total Costs: $1,882,315Grant Detail: The major goals are to establish the requirement, mechanism, and therapeutic implications of mutant MED12-mediated transcriptional reprogramming in uterine fibroid pathogenesis.

Funding Agency: NIH/NICHDGrant Number: R01 HD094378Title: Hypovitaminosis D promotes MED12-associated genomic instability in uterine fibroidsStatus: Active Period: 02/15/2018-01/31/2023Role: PI (20%)Total Costs: $3,912,724Grant Detail: The major goals are to establish the basis, define the mechanism, and explore the clinical implications of functional crosstalk between vitamin D3 and MED12 in UF genome maintenance.

Federal/State - Completed

Funding Agency: NIH/NIAGrant Number: R21 AG051962Title: Mediator as a transducer of Amyloid Precursor Protein-dependent nuclear signalingStatus: CompletePeriod: 08/01/2016-05/31/2018Role: PI (10%)Total Costs: $412,743Grant Detail: The major goals were to elucidate the mechanistic basis for coordinate transcriptional control by Amyloid Precursor Protein Intracellular Domain (AICD) and Mediator and determine the correlative relationship between Mediator-dependent AICD-target gene expression and AD severity.

Funding Agency: NIH/NIMHGrant Number: R01 MH085320-05Title: Mediator and epigenetic control of neuronal gene expression and differentiation Status: Lapsed – Voluntarily renewed by PI Period: 04/07/2009-07/31/2014Role: PI (20%)Total Costs: $1,853,645

40

Grant Detail: The major goal is to elucidate the mechanism of X-linked mental retardation-associated mutations in MED12 on REST-dependent suppression of neuronal gene expression and differentiation in neural progenitor cells.

Funding Agency: NIH/NIAMSGrant Number: R01 AR053100Title: Osteoblast differentiation: Interactions of Wnt, Runx2, and FGFStatus: Lapsed – Voluntarily not renewed by PI Period: 04/01/2008-03/31/2013Role: PI (20%)Total Costs: $1,455,450Grant Detail: The major goal was to establish the mechanistic basis and biological outcome for osteoblast differentiation of functional convergence of Wnt signaling and Runx2.

Funding Agency: NIH/NCIGrant Number: R01 CA098301Title: Modulation of estrogen receptor function by BRCA1Status: Lapsed - Voluntarily not renewed by PIPeriod: 01/01/2003 – 03/31/2008Role: PI (30%)Total Costs: $1,202,700Grant Detail: The major goals of this project were to elucidate the mechanism and regulation by which BRCA1 represses the ligand-independent transcriptional activity of the estrogen receptor and establish the biological role of BRCA1 in the control of cellular proliferation through ligand-independent transcriptional repression of the estrogen receptor.

Funding Agency: U.S. Army DoD, Breast Cancer Research Program IDEA AwardGrant Number: DAMD17-03-01-0272Title: BRCA1 regulation of estrogen signaling in the breastStatus: CompletePeriod: 05/01/2003 – 05/31/2007Role: PI (25%)Total Costs: $433,182Grant Detail: The major goals of this project were: (1) to biochemically reconstitute BRCA1-mediated ligand-independent repression of estrogen receptor alpha in vitro from purified components; (2) to examine the role of estrogen-induced site-specific phosphorylation in the regulation of BRCA1-mediated ligand-independent estrogen receptor alpha repression; and (3) to determine the role of BRCA1 in the control of paracrine growh signaling in the breast.

Funding Agency: U.S. Army DoD, Breast Cancer Research Program Career Development AwardGrant Number: DAMD17-02-01-0584Title: Regulation of BRCA1 function by DNA damage-induced site-specific phosphorylationStatus: CompletePeriod: 05/15/2002 – 05/31/2007Role: PI (50%)Total Costs: $176,515Grant Detail: The major goals of this project were: (1) to identify ionizing radiation-induced-induced site-specifically phosphorylated residues on BRCA1 in complex with transcription and DNA double-strand break repair activities; and (2) to determine the functional contribution of ionizing radiation-induced site-specific phosphorylation to the transcription and DNA-double strand break repair activities of BRCA1.

Funding Agency: NIH/NCITitle: BRCA1 and Transcriptional Control in DNA Damage ResponseStatus: CompletePeriod: 01/01/2002 – 01/31/2006Role: Co-Investigator (30%) (Lee, PI)

41

Total Costs: $1,460,000Grant Detail: The major goals of this project were: (1) to establish the role of ZBRK1 and BRCA1 in the coordinate transcriptional regulation of functionally diverse DNA damage-response genes; (2) to elucidate the role of ionizing radiation (IR)-induced site-specific phosphorylation on the network of functional interactions between ZBRK1 and its associated corepressors BRCA1 and CtIP in vivo; and (3) to establish the biological role of Ctip and Zbrk1 in response to IR in mice by germline inactivation of each corresponding gene.

Funding Agency: U.S. Army DoD, Breast Cancer Research Program Career Development AwardGrant Number: DAMD17-01-01-0408Title: Regulation of BRCA1 function by DNA damage-induced site-specific phosphorylationStatus: CompletePeriod: 05/01/2001 – 04/30/2004Role: PI (35%)Total Costs: $414,599Grant Detail: The major goals of this project were: (1) to identify ionizing radiation-induced-induced site-specifically phosphorylated residues on BRCA1 in complex with transcription and DNA double-strand break repair activities; and (2) to determine the functional contribution of ionizing radiation-induced site-specific phosphorylation to the transcription and DNA-double strand break repair activities of BRCA1.

Project #: 119238Funding Agency: National Cancer Institute/San Antonio Cancer InstituteTitle: IBT MALDI-TOF Mass Spectrometry Core Status: CompletePeriod: 08/01/2002 – 07/31/2003Role: PI (10%)Total Costs: $35,719Grant Detail: The major goals of this project were to provide investigators within the Department of Molecular Medicine, UTHSCSA, access to state-of-the-art mass spectrometry core services, including protein identification through peptide mass fingerprinting and characterization through MALDI-TOF analyses.

Private – Active

Funding Agency: William & Ella Owens Medical Research FoundationTitle: Precision targeting of MED12-mutant CLL with NOTCH inhibitorsStatus: ActivePeriod: 03/15/2017 - 06/30/2018Role: PI (10%)Total Costs: $100,000Grant Detail: The major goals are to examine the mechanistic relationship between MED12 mutations and pathological NICD stabilization and investigate the impact of NOTCH1 pathway inhibition on the oncogenic properties of MED12-mutant CLL.

Private – Completed

Funding Agency: Cancer Center CouncilTitle: Control of estrogen signaling by the breast cancer susceptibility gene product BRCA1Status: CompletePeriod: 8/01/2003 - 7/31/2004Role: PITotal Costs: $30,000Grant Detail: The major goals of this project were: (1) to biochemically purify and (2) to functionally characterize histone deacetylase-containing BRCA1 protein complexes responsible for suppression of ligand-independent estrogen receptor transcriptional activity.

42

Funding Agency: San Antonio Area FoundationTitle: Regulation of the breast tumor suppressor BRCA1 by site-specific phosphorylationStatus: CompletePeriod: 06/01/2001 - 05/31/2001Role: Pi (5%)Total Costs: $24,000Grant Detail: The major goals of this project were: (1) to identify ultraviolet radiation (UV)-induced site site-specifically phosphorylated residues on BRCA1; and (2) to determine the impact of UV-induced site-specific phosphorylation of BRCA1 on its transcriptional regulation of DNA damage response genes.

Other – Active

Funding Agency: CTRC Spore Pilot Project Title: SHH/GLI2 signaling axis as a therapeutic target in castration resistant prostate cancerStatus: ActivePeriod: 05/15/2017 - 08/15/2018Role: PI (10%)Total Costs: $30,000Grant Detail: The major goal is to understand how oncogenic mutations in the tumor suppressor SPOP abrogate a repressive arm of the SHH signaling axis and promote the development of castration resistant prostate cancer.

Funding Agency: GCCRI Pilot Project Title: Targeting the transcription dysregulation in Ewing sarcomaStatus: ActivePeriod: 05/01/2017 - 04/30/2019Role: co-PI (Bishop)Total Costs: $100,000Grant Detail: The major goal is to identify therapeutic targets that can be used in the treatment of Ewing sarcoma.

Other – Completed

Funding Agency: IIMS/CTSA/PCTCS Pilot Project Title: Targeting uterine fibroid stem cells with precision-based therapiesStatus: CompletePeriod: 09/01/2016 - 03/31/2018Role: PI (10%)Total Costs: $25,000Grant Detail: The major goals were to examine the impact of Wnt pathway inhibitors and glucocorticoid receptor agonists on the tumorigenic properties of MED12-mutant uterine fibroid stem cells both in vitro and in vivo.

Funding Agency: UTHSCSA VPR GrantSeekers Fund Title: Molecular basis of Mediator subunit 12 in uterine leiomyomagenesisStatus: ActivePeriod: 04/01/2015 - 03/31/2016Role: PI (10%)Total Costs: $30,000Grant Detail: The major goal is to elucidate the mechanism and therapeutic implications for uterine leiomyomata of altered Mediator-associated kinase activity arising from high-frequency recurrent mutations in Mediator subunit 12.

Funding Agency: UTHSCSA School of Medicine Bridge Funds

43

Title: Molecular basis of Mediator subunit 12 in the pathogenesis of uterine fibroidsStatus: ActivePeriod: 04/01/2016 - 03/31/2017Role: PI Total Costs: $50,000Grant Detail: The major goal is to strengthen existing and acquire new preliminary data, most notably through the use of a new murine kidney capsule xenograft model, in support of our ongoing project based on the role of MED12 in the pathogenesis of uterine fibroids.

Funding Agency: UTHSCSA VPR Research Enhancement Fund Title: Molecular basis of Mediator subunit 12 in the pathogenesis of uterine fibroidsStatus: CompletePeriod: 05/01/2014 - 06/30/2015Role: PI Total Costs: $45,000Grant Detail: The major goal was to develop infrastructure and expertise related to the isolation and characterization of human stem cells from myometrium and uterine leiomyomas for basic and applied research purposes.

Funding Agency: UTHSCSA Center for Biomedical Neuroscience CBN Pilot ProjectTitle: Mediator as a transducer of amyloid precursor protein-dependent nuclear signalingStatus: CompletePeriod: 01/01/2014 – 12//31/2014Role: PI (10%)Total Costs: $50,000Grant Detail: The major goal was to determine the correlative relationship between Mediator-dependent AICD-target gene expression and AD severity using both postmortem brain tissues from AD patients and a murine model of AD.

Funding Agency: Institute for Integration of Medicine & Science, Translational Technology ResourceTitle: Molecular basis of X-linked mental retardationStatus: CompletePeriod: 10/01/09 - 04/30/10Role: PI Total Costs: $9,390Grant Detail: The goal was to examine the impact of missense mutations in the RNA polymerase II transcriptional Mediator subunit MED12 responsible for the X-linked mental retardation disorders FG syndrome and Lujan syndrome on global Sonic hedgehog-dependent gene expression profiles using patient-derived cell lines and microarray technology.

Funding Agency: UTHSCSA Executive Research Council (ERC) Junior Investigator ProgramTitle: ERC Junior Faculty Research AwardStatus: CompletePeriod: 01/01/04 - 12/31/07Role: Principal InvestigatorTotal Costs: $3,809Grant Detail: Merit payment award in support of laboratory research activities.

Funding Agency: Cancer Therapy Research Center/San Antonio Cancer Institute Pilot Project Title: The role of BRCA1 as a coactivator of p53-dependent transcriptional activationStatus: CompletePeriod: 03/01/2000-07/31/01Role: PITotal Costs: $19,796Grant Detail: The major goals of this project were: (1) to determine the requirement for Brca1 in p53-

44

dependent transcriptional activation using cultured Brca1-deficient mouse embryo fibroblasts; and (2) to identify the mechanism through which Brca1 mediates p53-dependent transcriptional activation using a reconstituted in vitro transcription system.

Funding Agency: San Antonio Cancer Institute Women’s Cancer ProgramTitle: Modulation of estrogen receptor function by DBC-1Status: CompletePeriod: 05/01/08-04/30/09Role: Principal InvestigatorTotal Costs: $10,000Grant Detail: The major goal was to elucidate the mechanism by which DBC-1 and estrogen receptor collaborate to promote survival and suppress apoptosis of endocrine resistant breast cancer cells.

PATENTS:

Description Patent Category

Diagnosing and treating hormone resistant cancers, Patent#: US20090062179, Co-Inventor(s): Thomas G. Boyer and Amy M. TrauernichtAcquired resistance to endocrine therapy represents a major clinical roadblock to the successful management of estrogen-dependent breast cancers expressing estrogen receptor (ER). Our discovery that DBC-1 and ER collaborate to suppress apoptosis and promote endocrine resistant breast cancer cell growth and survival is a breakthrough discovery with immediate and far-reaching clinical implications for breast cancer prognosis and treatment. First, our results point to DBC-1 expression as valuable biomarker of breast tumor response to endocrine therapy. Second, the development of small molecule disruptors of the DBC-1/ER interface could provide a targeted means to selectively kill endocrine resistant breast tumor cells.

Biological

SERVICE

ADMINISTRATIVE RESPONSIBILITIES:

Dates Type Description Role

06/2009-Present Staff Supervised Michael Parker, Research Assistant Supervisor

09/2002-06/2008

01/2002-08/2002

Staff Supervised

Staff Supervised

Paula Garza, Research Associate

Rheanna Urrabaz, Research Assistant

Supervisor

Supervisor

SERVICE TO THE INSTITUTION:

DEPARTMENT


09/2000-Present

Department Molecular Medicine Annual Retreat Review Panel

Judge

45

Evaluate graduate student and postdoctoral fellow scientific presentations in order to determine presentation awardees.

09/2003- Present

Department Luminometer Shared Resource Supervisor

Manage use and maintain operation and oversight of department shared luminometer resources.

09/2000-05/2012

Department Molecular Medicine Graduate Program First-Year Student Mentor

Mentor

Mentor and advise first-year Molecular Medicine graduate students through monthly scheduled meetings.

07/2011- Department Institute of Biotechnology Author11/2011 Commercialization and Technology Development Plan

Compiled, edited, and wrote commercial and technology development plan for Institute of Biotechnology (Department of Molecular Medicine) commissioned by Department Chair. This report was designed to highlight IBT faculty research with potential commercial technology development applications.

09/2011- Department Molecular Medicine Seminar Series Chair12/2011

Coordinated weekly seminar series, to include identification of speakers and development of itineraries.

06/1999-08/2004

Department Summer Undergraduate Research Program

Mentor

Host and mentor to qualified undergraduate student interns participating in our SURF program for an 8-week summer research project in the laboratory.

09/2000-08/2001

Department Molecular Medicine Seminar Series Chair

Coordinated weekly seminar series, to include identification of speakers and development of itineraries.

SCHOOL


08/2015 School Cancer Research Summer Internship Program Capstone Poster Session

Judge

Participated in evaluation and selection of outstanding graduate student poster presentations at the

46

GSBS Annual Research Forum research poster competition.

01/2007 School GSBS Graduate Student Association Judge Annual Research Forum

Participated in evaluation and selection of outstanding graduate student poster presentations at the GSBS Annual Research Forum research poster competition.

01/2004-12/2004 School GSBS Post Baccalaureate Research Education Program (PREP)

Participant

Member of UTHSCSA PREP program designed to offer mentored research experience and preparation for graduate school to senior undergraduates or recent graduates holding a bachelor’s degree in biomedical or behavioral sciences.

01/2004-12/2004 School GSBS Alliances for Graduate Education and the Professioriate (AGEP) Program

Participant

Member of UTHSCSA AGEP program designed to increase number of underrepresented minorities obtaining graduate degrees in science and technology as well as enhance the preparation of underrepresented minorities for faculty positions in academia.

UNIVERSITY


09/2001-05/2005 University San Antonio Cancer Institute Mass Spectrometry Satellite Core

Director

Established and maintained oversight and operation of core facility designed to provide state-of-the-art mass spectrometry and proteomics services for research faculty within the Texas Research Park. Core services included peptide mass fingerprinting and protein sequence analysis through MALDI-TOF and ESI-MS, respectively, for protein identification and characterization.

SERVICE TO THE PROFESSION:


08/2009-Present

International International Journal of BiologicalSciences

Editorial BoardMember

01/2000-Present

International Cell, Science, Nature, PNAS, Nature Structural and Molecular Biology, Nature Chemical Biology, Nature Reviews Molecular Cellular Biology, Molecular Cell, Cell Stem Cell, Cell Reports, Cell Research, Genes & Development, Development, Journal of Biological

Journal Review

47

Chemistry, Cancer Research, Oncogene, Oncotarget, Cancer Investigation, Clinical Cancer Research, Molecular and Cellular Biology, Stem Cells, International Journal of Biological Sciences, PLoS ONE, PLoS Genetics, Stem Cell, Nucleic Acids Research, Journal of Pathology, Tumor Biology, Pharmacogenomics, Fertility and Sterility, Journal of Alzheimer’s Disease, BBA Gene Regulatory Mechanisms, Meta Gene, among others.

06/2015

05/2005

International

National

American Society for Reproductive Medicine 2015 Annual Meeting

ERA of HOPE U.S. Army DOD Breast Cancer Research Program Biennial Meeting, Philadelphia, PAHormonal Signaling Section

Abstract Reviewer

PlatformParticipant

05/2003 National ERA of HOPE U.S. Army DOD Breast Cancer Research Program Biennial Meeting, Philadelphia, PAHormonal Signaling Section

PlatformParticipant

01/2003 National National Cancer Institute 3rd Annual Division of Cancer Biology BRCA1 Workshop, Bethesda, MD

Participant

01/2001 National National Cancer Institute Division of Cancer Biology BRCA1 Workshop, Bethesda, MD

Participant

SERVICE TO THE PUBLIC:


08/2015-Present

02/2016

07/2013-10/2013

Community

Community

Community

Bonnie Ellison Elementary Watchdog Dad program

Bonnie Ellison ElementaryBuzzfest 2016

YMCA Youth Soccer League

Participant

Volunteer

Volunteer Coach

48

10/2009-06/2013

09/1999-09/1999

Community

Community

Leon Springs Elementary School Green Team Challenge

St. Edward's University Second Annual Career Opportunities Symposium for the School of Natural Sciences

Volunteer

UTHSCSA Representative

09/1999-09/1999

Community St. Edward's University Academic Society for the Advancement of Minorities in Medicine

Participant

01/2003-12/2004

Community Alamo Breast Cancer Foundation Patient Advocate Program

Advisor

09/2003-09/2003

Community Alamo Breast Cancer Foundation Annual

Guest

09/1991-09/1997

Community American Cancer Society Member

GRANT REVIEWS:

Dates Granting Agency Panel Name Role

02/2011

10/2010

10/2009

NIH/NIGMS

NIH/NCI

NIH/NCI

Molecular Genetics A

Cancer Molecular Pathology

Cancer Etiology

Member, Ad Hoc

Member,Ad Hoc

Member, Ad Hoc

01/2008 NIH/NCI Molecular Oncogenesis Member, Ad Hoc

03/2006 U.S. Army, DOD Breast Cancer Research Program

Concept Endocrinology 1 Member, Ad Hoc

07/2005 U.S. Army, DOD Breast CancerResearch Program

IDEA Endocrinology 1 Member, Ad Hoc

49

01/2003 U.S. Army, DOD Breast Cancer Research Program

Molecular Biology and Genetics

Member

PROFESSIONAL AFFILIATIONS:

Dates Organization

06/2015-Present

01/2003-12/2006

American Society for Reproductive Medicine

Alamo Breast Cancer Foundation

01/2000-Present San Antonio Cancer Institute

01/2000-Present Cancer Therapy and Research Center UTHSCSA

09/1998-08/1999 American Association for the Advancement of Science

COMMITTEES (UTHSCSA Standing Committees):

DEPARTMENT


09/2010-Present

Department Promotions Tenure andAppointment Committee

Chair

Evaluate and recommend, based on teaching, research, and service contributions, faculty within the Department of Molecular Medicine for promotion and/or tenure consideration.

09/2006- Department Promotions Tenure and Member Present Appointment Committee

50

Evaluate and recommend, based on teaching, research, and service contributions, faculty within the Department of Molecular Medicine for promotion and/or tenure consideration.

09/2008- Department Post Tenure Evaluation MemberPresent Committee

01/2011- Department Faculty Recruitment Chair05/2012 Committee

Identify, evaluate, interview, and recruit competitive applicants for junior and senior level faculty positions in the Department of Molecular Medicine and those with joint appointments with the Cancer Therapy Research Center (CTRC) and Veterans Administration (VA).

09/2001-05/2012

Department Graduate Program in Molecular Medicine Admission Committee

Member

Identify, evaluate, and interview applicants for the Graduate Program in Molecular Medicine.

09/2000-05/2012

Department Molecular Medicine Committee on Graduate Studies (COGS)

Member

Participate in the establishment of educational and ethical policies, procedures, and guidelines for the Molecular Medicine Graduate Program.

09/2003-11/2007

Department/Graduate Program

Molecular Medicine Committee on Graduate Studies (COGS)

Chair

Oversee and administer educational and ethical policies, procedures, and guidelines for the Molecular Medicine Graduate Program. Represent the Molecular Medicine Graduate Program and its constituent faculty on the Graduate Faculty Council, headed by the Graduate School Dean. Molecular Medicine Programmatic liaison to the Graduate Dean’s office. Preside over regularly scheduled COGS meetings to report Graduate Faculty Council proceedings.

SCHOOL


08/2012-Present

School IBMS Graduate Program Admissions Committee

Member

Identify, evaluate, interview, and recruit competitive applicants to the Integrated Biomedical Sciences Graduate program.

51

05/2014- School Cell Biology, Genetics, Member Present and Molecular Medicine (CGM) IBMS Discipline Leadership Committee

Participate in the development, review, and amendment of academic policies and procedures related to the CGM discipline, including student curriculum and academic guidelines, student recruitment, faculty appointments, and CGM outreach and advertisement.

08/2008- School Integrated Multidisciplinary Member 07/2012 Graduate Program (IMGP) Admissions Committee Identify, evaluate, interview, and recruit competitive applicants to the Integrated Multidisciplinary Graduate program.

09/2004-08/2007

School

Molecular Medicine Chair Search Committee

Molecular Medicine departmental representative on Dean’s committee to identity, evaluate, recruit, and recommend candidates to fill the vacant Molecular Medicine Chairmanship.

UNIVERSITY/CENTER


05/2013- Center Cancer Therapy Research Member Present Center (CTRC) Shared Resources Committee

Participate in evaluation and recommendation for improvements of CTRC shared resources core facilities, including Advanced Genomics (genomics, next generation sequencing & bioinformatics), Structure/Function (macromolecular structure & interactions, mass spectrometry), and Analytical (flow cytometry, optical imaging, and biostatistics) Cores. These evaluations include assessments and advisement on improved returns for value-added benefits, cost efficiencies, and other aspects of these CTRC cores.

03/2014- University UTHSCSA NMR MemberPresent Core Advisory Committee

Participate in evaluation and recommendation for improvements of UTHSCSA NMR Core facility. This evaluations include assessments and advisement concerning improved returns for value-added benefits, cost efficiencies, and other aspects of this UTHSCSA core.

09/2003- University Graduate Faculty Council Member11/2007

52

As Chair of the Molecular Medicine Committee on Graduate Studies (COGS), I was a member of the Graduate Faculty Council (GFC). This body is comprised of COGS chairs representing each of the graduate degree-granting educational program within UTHSCSA, including the Graduate School of Biomedical Sciences, the Dental School, the Nursing School, and School of Allied Health). The GFC is responsible for the establishment and administration of overall graduate school policies, including (but not limited to) creation of new or modifications to existing graduate programs, requirements for various admissions exams (MAT, GRE, DCAT, etc.), approval of awarding of degrees, dissertation supervising committees, supervising professors, dissertation research proposals, etc.

COMMITTEES (OTHER):

DEPARTMENT


09/2003-Present

Department Department of Molecular Medicine Shared Instrumentation Committee

Member

Participate in the establishment of policies for use of shared equipment.

01/2011- Department Faculty Recruitment Committee Chair03/2012

Identify, evaluate, interview, and recruit competitive applicants for junior and senior level faculty positions in the Department of Molecular Medicine and those with joint appointments with the Cancer Therapy Research Center (CTRC) and Veterans Administration (VA).

09/2000-05/2012

Department Graduate Program in Molecular Medicine Qualifying Examination Committee

Member

Participate in the evaluation and recommendation, based on critical review of an original written research proposal and its oral defense, of student suitability for advancement to Ph.D. candidacy.

09/2000- 05/2012

Department Graduate Program in Molecular Medicine Comprehensive Examinations Committee

Member

Participate in the evaluation and recommendation, based on overall academic performance, laboratory rotation evaluations, and a year-end oral examination, of student suitability for advancement to the second year of the Molecular Medicine Ph.D. training.

09/2003-12/2003

Department Department of Molecular Medicine Self-Study Committee

Member

53

As chair of the Committee on Graduate Studies, I served as a contributing writer and editor of our Departmental Self Study, a comprehensive overview and critical evaluation of our Educational and Research Programs commissioned by the Graduate School Dean’s office.

09/1999-08/2000

Department Graduate Program in Molecular Medicine Student Recruitment Committee

Member

Host and recruit Molecular Medicine Gradate Program applicants during visit to UTHSCSA.

SCHOOL


06/2007-07/2008

School MD/Ph.D. Admissions Committee Member

Participate in the evaluation and recommendation of competitive applications for admission to the combined MD/PhD program.

09/2004-08/2007

School GSBS Armand J. Guarino Awards for Academic Excellence Selection Committee

Member

Participated in annual competitive evaluation and selection of individual student awardees recognized for outstanding academic and research achievement in Doctoral and Master’s studies.

01/2006-12/2006

School GSBS Integrated Multidisciplinary Graduate Program (IMGP) Curriculum Development Committee

Member

Participated in establishing the core course curriculum for the newly established IMGP umbrella program at UTHSCSA.

09/2004-08/2005 School GSBS Barbara H. Bowman Postdoctoral Research Awards for Academic Excellence Selection Committee

Member

Participated in annual competitive evaluation and selection of individual postdoctoral student awardee recognized for outstanding research achievement.

54

curriculum vitae - chicago medicine · web viewsupervised the research project of mr. lessner, an...

Documents